

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

F1_M3

C Number: C99024C
Lock Date: 06/29/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF Androstenedione

MALE MICE

Organ

Adrenal Cortex
Adrenal Cortex: Capsule
Bone Marrow
Eye
Islets, Pancreatic
Kidney: Renal Tubule

Liver

Lymph Node, Mandibular
Lymph Node, Mesenteric
Mesentery
Nose
Peripheral Nerve
Prostate
Spleen: Lymphoid Follicle
Thymus

Thyroid Gland: Follicular Cell

FEMALE MICE

Organ

Bone Marrow
Clitoral Gland
Clitoral Gland: Duct
Kidney

Kidney: Glomerulus
Liver

Morphology

Accessory Adrenal Cortical Nodule
Hyperplasia
Hyperplasia
Inflammation Chronic
Hyperplasia
Hyperplasia
Pigmentation
Clear Cell Focus
Eosinophilic Focus
Hematopoietic Cell Proliferation
Infiltration Cellular Mixed Cell
Atrophy
Atrophy
Hemorrhage
Foreign Body
Atrophy
Inflammation Chronic
Atrophy
Atrophy
Cyst
Hyperplasia

Morphology

Hyperplasia
Hyperplasia
Dilatation
Glomerulosclerosis
Infarct
Metaplasia
Basophilic Focus

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Androstenedione

Liver: Hepatocyte	Mixed Cell Focus
Liver: Kupffer Cell	Vacuolization Cytoplasmic
Lung	Pigmentation
Lymph Node, Mesenteric	Hemorrhage
Lymph Node: Iliac	Hyperplasia Lymphoid
Mesentery: Fat	Hematopoietic Cell Proliferation
Ovary	Necrosis
	Angiectasis
Pancreas	Hemorrhage
	Atrophy
Peripheral Nerve	Cyst
Salivary Glands	Atrophy
Salivary Glands: Submandibular Gland	Infiltration Cellular Lymphocyte
Spleen	Cytoplasmic Alteration
Spleen: Lymphoid Follicle	Hematopoietic Cell Proliferation
Stomach, Forestomach: Epithelium	Hyperplasia
Stomach, Glandular	Hyperplasia
Thyroid Gland: Follicle	Cyst
Uterus	Degeneration Focal
	Angiectasis
	Hyperplasia Cystic

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Accessory Adrenal Cortical Nodule**

LESION RATES

OVERALL (a)	6/50 (12%)	1/49 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	6/45.38	1/47.36	3/44.91	2/45.17
POLY-3 PERCENT (g)	13.2%	2.1%	6.7%	4.4%
TERMINAL (d)	2/36 (6%)	1/43 (2%)	2/34 (6%)	2/37 (5%)
FIRST INCIDENCE	489	729 (T)	540	729 (T)

STATISTICAL TESTS

POLY 3	P=0.203N	P=0.049N*	P=0.247N	P=0.134N
POLY 1.5	P=0.197N	P=0.053N	P=0.248N	P=0.134N
POLY 6	P=0.211N	P=0.045N*	P=0.245N	P=0.134N
COCH-ARM / FISHERS	P=0.188N	P=0.059N	P=0.243N	P=0.134N
MAX-ISO-POLY-3	P=0.071N	P=0.023N*	P=0.151N	P=0.070N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	4/50 (8%)	5/49 (10%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	4/43.30	5/47.36	5/44.32	3/45.17
POLY-3 PERCENT (g)	9.2%	10.6%	11.3%	6.6%
TERMINAL (d)	4/36 (11%)	5/43 (12%)	5/34 (15%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.357N	P=0.556	P=0.515	P=0.477N
POLY 1.5	P=0.360N	P=0.528	P=0.505	P=0.486N
POLY 6	P=0.354N	P=0.587	P=0.526	P=0.465N
COCH-ARM / FISHERS	P=0.363N	P=0.487	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.453N	P=0.419	P=0.377	P=0.329N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Hypertrophy Focal**

LESION RATES

OVERALL (a)	10/50 (20%)	7/49 (14%)	11/50 (22%)	9/50 (18%)
POLY-3 RATE (b)	10/43.30	7/47.37	11/44.33	9/45.17
POLY-3 PERCENT (g)	23.1%	14.8%	24.8%	19.9%
TERMINAL (d)	10/36 (28%)	6/43 (14%)	10/34 (29%)	9/37 (24%)
FIRST INCIDENCE	729 (T)	725	725	729 (T)

STATISTICAL TESTS

POLY 3	P=0.558N	P=0.229N	P=0.525	P=0.459N
POLY 1.5	P=0.554N	P=0.262N	P=0.509	P=0.476N
POLY 6	P=0.557	P=0.194N	P=0.545	P=0.437N
COCH-ARM / FISHERS	P=0.551N	P=0.314N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.542	P=0.168N	P=0.424	P=0.360N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex: Capsule
 Hyperplasia**

LESION RATES

OVERALL (a)	5/50 (10%)	4/49 (8%)	5/50 (10%)	10/50 (20%)
POLY-3 RATE (b)	5/43.30	4/47.37	5/44.32	10/45.80
POLY-3 PERCENT (g)	11.6%	8.4%	11.3%	21.8%
TERMINAL (d)	5/36 (14%)	3/43 (7%)	5/34 (15%)	9/37 (24%)
FIRST INCIDENCE	729 (T)	725	729 (T)	526

STATISTICAL TESTS

POLY 3	P=0.047*	P=0.444N	P=0.616N	P=0.155
POLY 1.5	P=0.047*	P=0.471N	P=0.625N	P=0.144
POLY 6	P=0.047*	P=0.412N	P=0.605N	P=0.168
COCH-ARM / FISHERS	P=0.047*	P=0.513N	P=0.630N	P=0.131
MAX-ISO-POLY-3	P=0.073	P=0.320N	P=0.484N	P=0.102

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Medulla
 Hyperplasia**

LESION RATES

OVERALL (a)	0/49 (0%)	0/49 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.30	0/47.36	1/44.58	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/35 (0%)	0/43 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	660	---

STATISTICAL TESTS

POLY 3	P=0.787N	(e)	P=0.510	(e)
POLY 1.5	P=0.786N	(e)	P=0.507	(e)
POLY 6	P=0.787N	(e)	P=0.515	(e)
COCH-ARM / FISHERS	P=0.787N	(e)	P=0.505	(e)
MAX-ISO-POLY-3	P=0.405	(e)	P=0.170	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone Marrow
 Hyperplasia**

LESION RATES

OVERALL (a)	19/50 (38%)	30/50 (60%)	23/50 (46%)	30/50 (60%)
POLY-3 RATE (b)	19/46.69	30/49.72	23/47.55	30/49.29
POLY-3 PERCENT (g)	40.7%	60.3%	48.4%	60.9%
TERMINAL (d)	11/36 (31%)	25/44 (57%)	12/34 (35%)	18/37 (49%)
FIRST INCIDENCE	534	593	256	493

STATISTICAL TESTS

POLY 3	P=0.085	P=0.040*	P=0.293	P=0.036*
POLY 1.5	P=0.074	P=0.032*	P=0.281	P=0.029*
POLY 6	P=0.100	P=0.050*	P=0.310	P=0.045*
COCH-ARM / FISHERS	P=0.061	P=0.022*	P=0.272	P=0.022*
MAX-ISO-POLY-3	P=0.040*	P=0.028*	P=0.229	P=0.025*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone
 Fibrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Bone: Cranium
 Osteopetrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/43.30	0/48.36	1/44.32	2/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	4.4%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	2/37 (5%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.080	(e)	P=0.505	P=0.247
POLY 1.5	P=0.080	(e)	P=0.502	P=0.243
POLY 6	P=0.079	(e)	P=0.508	P=0.251
COCH-ARM / FISHERS	P=0.081	(e)	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.090	(e)	P=0.164	P=0.085

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Brain
Compression**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/43.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Eye
 Cataract**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.30	1/48.39	0/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	0%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	721	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.679	P=0.735N	P=0.495N	P=0.751N
POLY 1.5	P=0.679N	P=0.745N	P=0.498N	P=0.755N
POLY 6	P=0.680	P=0.723N	P=0.492N	P=0.746N
COCH-ARM / FISHERS	P=0.680	P=0.753N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.534N	P=0.469N	P=0.158N	P=0.487N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Eye
 Inflammation Chronic**

LESION RATES

OVERALL (a)	3/50 (6%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	3/43.30	1/48.36	2/44.66	0/45.17
POLY-3 PERCENT (g)	6.9%	2.1%	4.5%	0%
TERMINAL (d)	3/36 (8%)	1/44 (2%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	660	---

STATISTICAL TESTS

POLY 3	P=0.116N	P=0.267N	P=0.486N	P=0.111N
POLY 1.5	P=0.114N	P=0.282N	P=0.495N	P=0.114N
POLY 6	P=0.119N	P=0.250N	P=0.474N	P=0.107N
COCH-ARM / FISHERS	P=0.111N	P=0.309N	P=0.500N	P=0.121N
MAX-ISO-POLY-3	P=0.060N	P=0.141N	P=0.314N	P=0.038N*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Eye: Cornea
 Hyperplasia

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.30	1/48.36	0/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	0%	2.2%
TERMINAL (d)	1/36 (3%)	1/44 (2%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.680	P=0.735N	P=0.495N	P=0.751N
POLY 1.5	P=0.679N	P=0.746N	P=0.498N	P=0.755N
POLY 6	P=0.680	P=0.723N	P=0.492N	P=0.746N
COCH-ARM / FISHERS	P=0.680	P=0.753N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.534N	P=0.469N	P=0.158N	P=0.487N

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Harderian Gland
Hyperplasia Focal**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Heart
 Cardiomyopathy**

LESION RATES

OVERALL (a)	4/50 (8%)	4/50 (8%)	5/50 (10%)	7/50 (14%)
POLY-3 RATE (b)	4/44.08	4/48.80	5/45.11	7/45.81
POLY-3 PERCENT (g)	9.1%	8.2%	11.1%	15.3%
TERMINAL (d)	2/36 (6%)	2/44 (5%)	1/34 (3%)	4/37 (11%)
FIRST INCIDENCE	534	606	620	638

STATISTICAL TESTS

POLY 3	P=0.172	P=0.586N	P=0.515	P=0.283
POLY 1.5	P=0.172	P=0.609N	P=0.505	P=0.274
POLY 6	P=0.172	P=0.559N	P=0.528	P=0.296
COCH-ARM / FISHERS	P=0.172	P=0.643N	P=0.500	P=0.262
MAX-ISO-POLY-3	P=0.264	P=0.442N	P=0.377	P=0.190

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Islets, Pancreatic
 Hyperplasia**

LESION RATES

OVERALL (a)	12/50 (24%)	14/50 (28%)	11/50 (22%)	6/49 (12%)
POLY-3 RATE (b)	12/44.83	14/48.37	11/44.92	6/44.74
POLY-3 PERCENT (g)	26.8%	28.9%	24.5%	13.4%
TERMINAL (d)	9/36 (25%)	13/44 (30%)	8/34 (24%)	4/37 (11%)
FIRST INCIDENCE	513	725	631	638

STATISTICAL TESTS

POLY 3	P=0.048N*	P=0.499	P=0.498N	P=0.093N
POLY 1.5	P=0.048N*	P=0.464	P=0.505N	P=0.097N
POLY 6	P=0.047N*	P=0.538	P=0.487N	P=0.087N
COCH-ARM / FISHERS	P=0.049N*	P=0.410	P=0.500N	P=0.104N
MAX-ISO-POLY-3	P=0.075N	P=0.409	P=0.400N	P=0.056N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Cyst**

LESION RATES

OVERALL (a)	9/50 (18%)	16/50 (32%)	9/50 (18%)	13/50 (26%)
POLY-3 RATE (b)	9/43.85	16/48.36	9/44.44	13/45.17
POLY-3 PERCENT (g)	20.5%	33.1%	20.3%	28.8%
TERMINAL (d)	8/36 (22%)	16/44 (36%)	7/34 (21%)	13/37 (35%)
FIRST INCIDENCE	556	729 (T)	701	729 (T)

STATISTICAL TESTS

POLY 3	P=0.383	P=0.130	P=0.592N	P=0.255
POLY 1.5	P=0.381	P=0.109	P=0.601N	P=0.247
POLY 6	P=0.384	P=0.159	P=0.579N	P=0.266
COCH-ARM / FISHERS	P=0.378	P=0.083	P=0.602N	P=0.235
MAX-ISO-POLY-3	P=0.309	P=0.097	P=0.487N	P=0.186

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
Glomerulosclerosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Hydronephrosis**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/43.30	2/48.78	1/44.50	2/45.88
POLY-3 PERCENT (g)	2.3%	4.1%	2.3%	4.4%
TERMINAL (d)	1/36 (3%)	1/44 (2%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	606	683	485

STATISTICAL TESTS

POLY 3	P=0.469	P=0.541	P=0.755N	P=0.520
POLY 1.5	P=0.464	P=0.525	P=0.758N	P=0.512
POLY 6	P=0.473	P=0.561	P=0.750N	P=0.530
COCH-ARM / FISHERS	P=0.456	P=0.500	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.484	P=0.325	P=0.491N	P=0.303

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Infarct**

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	4/43.30	2/48.64	1/44.67	5/45.50
POLY-3 PERCENT (g)	9.2%	4.1%	2.2%	11%
TERMINAL (d)	4/36 (11%)	1/44 (2%)	0/34 (0%)	4/37 (11%)
FIRST INCIDENCE	729 (T)	652	631	638

STATISTICAL TESTS

POLY 3	P=0.280	P=0.286N	P=0.169N	P=0.531
POLY 1.5	P=0.284	P=0.306N	P=0.175N	P=0.518
POLY 6	P=0.276	P=0.262N	P=0.161N	P=0.548
COCH-ARM / FISHERS	P=0.289	P=0.339N	P=0.181N	P=0.500
MAX-ISO-POLY-3	P=0.228	P=0.175N	P=0.081N	P=0.393

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	5/50 (10%)	2/50 (4%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	5/43.63	2/48.36	4/44.70	5/45.47
POLY-3 PERCENT (g)	11.5%	4.1%	9%	11%
TERMINAL (d)	4/36 (11%)	2/44 (5%)	3/34 (9%)	4/37 (11%)
FIRST INCIDENCE	636	729 (T)	620	648

STATISTICAL TESTS

POLY 3	P=0.407	P=0.177N	P=0.485N	P=0.604N
POLY 1.5	P=0.412	P=0.192N	P=0.495N	P=0.615N
POLY 6	P=0.402	P=0.161N	P=0.473N	P=0.591N
COCH-ARM / FISHERS	P=0.417	P=0.218N	P=0.500N	P=0.630N
MAX-ISO-POLY-3	P=0.458N	P=0.104N	P=0.350N	P=0.472N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Inflammation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	1/44.44	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	698	---

STATISTICAL TESTS

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.509	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.165	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Metaplasia Osseous**

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	5/50 (10%)	4/50 (8%)
POLY-3 RATE (b)	4/43.63	2/48.36	5/44.91	4/45.17
POLY-3 PERCENT (g)	9.2%	4.1%	11.1%	8.9%
TERMINAL (d)	3/36 (8%)	2/44 (5%)	4/34 (12%)	4/37 (11%)
FIRST INCIDENCE	636	729 (T)	540	729 (T)

STATISTICAL TESTS

POLY 3	P=0.461	P=0.291N	P=0.518	P=0.624N
POLY 1.5	P=0.466	P=0.309N	P=0.507	P=0.632N
POLY 6	P=0.455	P=0.272N	P=0.530	P=0.616N
COCH-ARM / FISHERS	P=0.471	P=0.339N	P=0.500	P=0.643N
MAX-ISO-POLY-3	P=0.454	P=0.178N	P=0.381	P=0.479N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Mineralization**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	2/44.58	0/45.17
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	683	---

STATISTICAL TESTS

POLY 3	P=0.717N	(e)	P=0.244	(e)
POLY 1.5	P=0.717N	(e)	P=0.240	(e)
POLY 6	P=0.717N	(e)	P=0.249	(e)
COCH-ARM / FISHERS	P=0.716	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.265	(e)	P=0.082	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney
 Nephropathy**

LESION RATES

OVERALL (a)	38/50 (76%)	45/50 (90%)	38/50 (76%)	44/50 (88%)
POLY-3 RATE (b)	38/46.77	45/49.72	38/46.43	44/48.87
POLY-3 PERCENT (g)	81.3%	90.5%	81.8%	90%
TERMINAL (d)	31/36 (86%)	40/44 (91%)	31/34 (91%)	35/37 (95%)
FIRST INCIDENCE	513	593	472	485

STATISTICAL TESTS

POLY 3	P=0.224	P=0.142	P=0.581	P=0.159
POLY 1.5	P=0.201	P=0.097	P=0.568	P=0.129
POLY 6	P=0.249	P=0.215	P=0.602	P=0.202
COCH-ARM / FISHERS	P=0.172	P=0.054	P=0.592N	P=0.096
MAX-ISO-POLY-3	P=0.159	P=0.090	P=0.468	P=0.100

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Glomerulus
 Metaplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	1/44.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	725	---

STATISTICAL TESTS

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Hyperplasia**

LESION RATES

OVERALL (a)	7/50 (14%)	6/50 (12%)	6/50 (12%)	2/50 (4%)
POLY-3 RATE (b)	7/43.75	6/48.36	6/44.32	2/45.17
POLY-3 PERCENT (g)	16%	12.4%	13.5%	4.4%
TERMINAL (d)	6/36 (17%)	6/44 (14%)	6/34 (18%)	2/37 (5%)
FIRST INCIDENCE	597	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.062N	P=0.423N	P=0.490N	P=0.071N
POLY 1.5	P=0.061N	P=0.454N	P=0.498N	P=0.074N
POLY 6	P=0.062N	P=0.390N	P=0.481N	P=0.067N
COCH-ARM / FISHERS	P=0.062N	P=0.500N	P=0.500N	P=0.080N
MAX-ISO-POLY-3	P=0.075N	P=0.320N	P=0.372N	P=0.036N*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Pigmentation**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	1/43.30	3/48.82	6/45.00	3/45.17
POLY-3 PERCENT (g)	2.3%	6.2%	13.3%	6.6%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	4/34 (12%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	593	631	729 (T)

STATISTICAL TESTS

POLY 3	P=0.357	P=0.350	P=0.062	P=0.320
POLY 1.5	P=0.355	P=0.332	P=0.058	P=0.314
POLY 6	P=0.360	P=0.372	P=0.067	P=0.328
COCH-ARM / FISHERS	P=0.351	P=0.309	P=0.056	P=0.309
MAX-ISO-POLY-3	P=0.139	P=0.199	P=0.028*	P=0.170

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Basophilic Focus

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.30	2/48.36	1/44.32	1/45.20
POLY-3 PERCENT (g)	2.3%	4.1%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	723

STATISTICAL TESTS

POLY 3	P=0.540N	P=0.538	P=0.756N	P=0.751N
POLY 1.5	P=0.543N	P=0.523	P=0.759N	P=0.755N
POLY 6	P=0.537N	P=0.556	P=0.752N	P=0.746N
COCH-ARM / FISHERS	P=0.548N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.603N	P=0.322	P=0.493N	P=0.487N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Clear Cell Focus

LESION RATES

OVERALL (a)	27/50 (54%)	24/50 (48%)	18/50 (36%)	12/50 (24%)
POLY-3 RATE (b)	27/43.75	24/48.80	18/44.32	12/46.03
POLY-3 PERCENT (g)	61.7%	49.2%	40.6%	26.1%
TERMINAL (d)	26/36 (72%)	22/44 (50%)	18/34 (53%)	10/37 (27%)
FIRST INCIDENCE	597	606	729 (T)	485

STATISTICAL TESTS

POLY 3	P<0.001N**	P=0.154N	P=0.033N*	P<0.001N**
POLY 1.5	P<0.001N**	P=0.223N	P=0.042N*	P<0.001N**
POLY 6	P<0.001N**	P=0.092N	P=0.024N*	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.345N	P=0.054N	P=0.002N**
MAX-ISO-POLY-3	P<0.001N**	P=0.121N	P=0.020N*	P<0.001N**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Cyst

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/43.30	0/48.36	0/44.32	2/45.17
POLY-3 PERCENT (g)	2.3%	0%	0%	4.4%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	0/34 (0%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.210	P=0.478N	P=0.495N	P=0.515
POLY 1.5	P=0.214	P=0.487N	P=0.498N	P=0.509
POLY 6	P=0.206	P=0.468N	P=0.492N	P=0.522
COCH-ARM / FISHERS	P=0.218	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.149	P=0.158N	P=0.158N	P=0.297

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Eosinophilic Focus

LESION RATES

OVERALL (a)	13/50 (26%)	10/50 (20%)	11/50 (22%)	25/50 (50%)
POLY-3 RATE (b)	13/44.43	10/48.39	11/44.57	25/46.36
POLY-3 PERCENT (g)	29.3%	20.7%	24.7%	53.9%
TERMINAL (d)	10/36 (28%)	9/44 (21%)	9/34 (27%)	21/37 (57%)
FIRST INCIDENCE	581	721	673	513

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.237N	P=0.402N	P=0.012*
POLY 1.5	P<0.001**	P=0.267N	P=0.410N	P=0.011*
POLY 6	P<0.001**	P=0.207N	P=0.394N	P=0.014*
COCH-ARM / FISHERS	P<0.001**	P=0.318N	P=0.408N	P=0.011*
MAX-ISO-POLY-3	P<0.001**	P=0.180N	P=0.314N	P=0.008**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	1/48.82	4/45.27	0/45.17
POLY-3 PERCENT (g)	0%	2.1%	8.8%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	3/34 (9%)	0/37 (0%)
FIRST INCIDENCE	---	593	256	---

STATISTICAL TESTS

POLY 3	P=0.542N	P=0.524	P=0.066	(e)
POLY 1.5	P=0.544N	P=0.514	P=0.064	(e)
POLY 6	P=0.539N	P=0.535	P=0.069	(e)
COCH-ARM / FISHERS	P=0.548N	P=0.500	P=0.059	(e)
MAX-ISO-POLY-3	P=0.170	P=0.188	P=0.024*	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver
 Infiltration Cellular**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	2/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	2/34 (6%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.717N	(e)	P=0.242	(e)
POLY 1.5	P=0.717N	(e)	P=0.239	(e)
POLY 6	P=0.717N	(e)	P=0.246	(e)
COCH-ARM / FISHERS	P=0.716	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.264	(e)	P=0.081	(e)

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
Infiltration Cellular Lymphocyte

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

.....
STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Infiltration Cellular Mixed Cell

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	1/43.79	1/48.36	5/44.71	2/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	11.2%	4.4%
TERMINAL (d)	0/36 (0%)	1/44 (2%)	3/34 (9%)	2/37 (5%)
FIRST INCIDENCE	581	729 (T)	631	729 (T)

STATISTICAL TESTS

POLY 3	P=0.388	P=0.738N	P=0.106	P=0.511
POLY 1.5	P=0.390	P=0.747N	P=0.103	P=0.507
POLY 6	P=0.385	P=0.727N	P=0.110	P=0.516
COCH-ARM / FISHERS	P=0.392	P=0.753N	P=0.102	P=0.500
MAX-ISO-POLY-3	P=0.185	P=0.472N	P=0.048*	P=0.292

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Mixed Cell Focus

LESION RATES

OVERALL (a)	10/50 (20%)	10/50 (20%)	11/50 (22%)	13/50 (26%)
POLY-3 RATE (b)	10/43.30	10/48.37	11/44.35	13/45.88
POLY-3 PERCENT (g)	23.1%	20.7%	24.8%	28.3%
TERMINAL (d)	10/36 (28%)	9/44 (21%)	10/34 (29%)	12/37 (32%)
FIRST INCIDENCE	729 (T)	725	720	485

STATISTICAL TESTS

POLY 3	P=0.259	P=0.489N	P=0.525	P=0.373
POLY 1.5	P=0.256	P=0.534N	P=0.509	P=0.350
POLY 6	P=0.262	P=0.437N	P=0.546	P=0.401
COCH-ARM / FISHERS	P=0.247	P=0.598N	P=0.500	P=0.318
MAX-ISO-POLY-3	P=0.396	P=0.393N	P=0.425	P=0.292

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Necrosis Focal

LESION RATES

OVERALL (a)	3/50 (6%)	3/50 (6%)	5/50 (10%)	6/50 (12%)
POLY-3 RATE (b)	3/45.02	3/48.36	5/45.53	6/45.80
POLY-3 PERCENT (g)	6.7%	6.2%	11%	13.1%
TERMINAL (d)	0/36 (0%)	3/44 (7%)	1/34 (3%)	4/37 (11%)
FIRST INCIDENCE	398	729 (T)	472	586

STATISTICAL TESTS

POLY 3	P=0.150	P=0.629N	P=0.363	P=0.250
POLY 1.5	P=0.152	P=0.642N	P=0.357	P=0.247
POLY 6	P=0.149	P=0.613N	P=0.371	P=0.256
COCH-ARM / FISHERS	P=0.155	P=0.661N	P=0.357	P=0.243
MAX-ISO-POLY-3	P=0.226	P=0.464N	P=0.238	P=0.155

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Tension Lipidosis

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	1/45.17
POLY-3 PERCENT (g)	0%	0%	0%	2.2%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.210	(e)	(e)	P=0.508
POLY 1.5	P=0.211	(e)	(e)	P=0.505
POLY 6	P=0.210	(e)	(e)	P=0.513
COCH-ARM / FISHERS	P=0.211	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.139	(e)	(e)	P=0.169

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Centrilobular
 Necrosis

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	2/44.10	0/48.36	3/45.33	4/47.43
POLY-3 PERCENT (g)	4.5%	0%	6.6%	8.4%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	590	---	613	485

STATISTICAL TESTS

POLY 3	P=0.122	P=0.217N	P=0.513	P=0.371
POLY 1.5	P=0.120	P=0.225N	P=0.505	P=0.358
POLY 6	P=0.123	P=0.209N	P=0.523	P=0.386
COCH-ARM / FISHERS	P=0.118	P=0.247N	P=0.500	P=0.339
MAX-ISO-POLY-3	P=0.143	P=0.076N	P=0.337	P=0.235

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Hepatocyte
 Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	17/50 (34%)	14/50 (28%)	14/50 (28%)	12/50 (24%)
POLY-3 RATE (b)	17/44.13	14/48.37	14/45.23	12/45.73
POLY-3 PERCENT (g)	38.5%	28.9%	31%	26.2%
TERMINAL (d)	16/36 (44%)	13/44 (30%)	13/34 (38%)	11/37 (30%)
FIRST INCIDENCE	398	725	318	554

STATISTICAL TESTS

POLY 3	P=0.186N	P=0.225N	P=0.297N	P=0.151N
POLY 1.5	P=0.188N	P=0.268N	P=0.317N	P=0.168N
POLY 6	P=0.181N	P=0.177N	P=0.273N	P=0.131N
COCH-ARM / FISHERS	P=0.190N	P=0.333N	P=0.333N	P=0.189N
MAX-ISO-POLY-3	P=0.175N	P=0.175N	P=0.227N	P=0.107N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver: Kupffer Cell
 Pigmentation

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Hemorrhage**

LESION RATES

OVERALL (a)	4/50 (8%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	4/44.08	1/48.36	1/44.70	2/45.50
POLY-3 PERCENT (g)	9.1%	2.1%	2.2%	4.4%
TERMINAL (d)	2/36 (6%)	1/44 (2%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	581	729 (T)	620	638

STATISTICAL TESTS

POLY 3	P=0.400N	P=0.152N	P=0.174N	P=0.322N
POLY 1.5	P=0.395N	P=0.162N	P=0.178N	P=0.328N
POLY 6	P=0.407N	P=0.142N	P=0.170N	P=0.316N
COCH-ARM / FISHERS	P=0.386N	P=0.181N	P=0.181N	P=0.339N
MAX-ISO-POLY-3	P=0.129N	P=0.077N	P=0.082N	P=0.193N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	10/50 (20%)	5/50 (10%)	5/50 (10%)	11/50 (22%)
POLY-3 RATE (b)	10/44.85	5/48.39	5/44.58	11/45.32
POLY-3 PERCENT (g)	22.3%	10.3%	11.2%	24.3%
TERMINAL (d)	5/36 (14%)	4/44 (9%)	4/34 (12%)	9/37 (24%)
FIRST INCIDENCE	581	721	660	708

STATISTICAL TESTS

POLY 3	P=0.225	P=0.098N	P=0.130N	P=0.511
POLY 1.5	P=0.235	P=0.109N	P=0.132N	P=0.508
POLY 6	P=0.214	P=0.088N	P=0.131N	P=0.510
COCH-ARM / FISHERS	P=0.249	P=0.131N	P=0.131N	P=0.500
MAX-ISO-POLY-3	P=0.175	P=0.064N	P=0.080N	P=0.411

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Thrombosis**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.83	0/48.36	1/44.72	0/45.17
POLY-3 PERCENT (g)	4.5%	0%	2.2%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	398	---	613	---

STATISTICAL TESTS

POLY 3	P=0.230N	P=0.221N	P=0.501N	P=0.235N
POLY 1.5	P=0.225N	P=0.228N	P=0.503N	P=0.237N
POLY 6	P=0.235N	P=0.212N	P=0.496N	P=0.233N
COCH-ARM / FISHERS	P=0.218N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.078N	P=0.076N	P=0.281N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung: Alveolar Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	4/43.79	2/48.37	2/44.32	3/45.80
POLY-3 PERCENT (g)	9.1%	4.1%	4.5%	6.6%
TERMINAL (d)	3/36 (8%)	1/44 (2%)	2/34 (6%)	2/37 (5%)
FIRST INCIDENCE	581	725	729 (T)	526

STATISTICAL TESTS

POLY 3	P=0.539N	P=0.293N	P=0.331N	P=0.476N
POLY 1.5	P=0.536N	P=0.310N	P=0.336N	P=0.485N
POLY 6	P=0.543N	P=0.273N	P=0.326N	P=0.464N
COCH-ARM / FISHERS	P=0.533N	P=0.339N	P=0.339N	P=0.500N
MAX-ISO-POLY-3	P=0.352N	P=0.179N	P=0.197N	P=0.329N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node, Mandibular Atrophy

LESION RATES

OVERALL (a)	0/47 (0%)	0/47 (0%)	3/47 (6%)	0/47 (0%)
POLY-3 RATE (b)	0/41.36	0/45.36	3/43.61	0/42.86
POLY-3 PERCENT (g)	0%	0%	6.9%	0%
TERMINAL (d)	0/35 (0%)	0/41 (0%)	0/33 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	613	---

STATISTICAL TESTS

POLY 3	P=0.682N	(e)	P=0.128	(e)
POLY 1.5	P=0.681N	(e)	P=0.123	(e)
POLY 6	P=0.682N	(e)	P=0.135	(e)
COCH-ARM / FISHERS	P=0.680	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.183	(e)	P=0.046*	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node, Mandibular Hemorrhage

LESION RATES

OVERALL (a)	0/47 (0%)	0/47 (0%)	0/47 (0%)	0/47 (0%)
POLY-3 RATE (b)	0/41.36	0/45.36	0/42.64	0/42.86
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/41 (0%)	0/33 (0%)	0/35 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mandibular
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	5/47 (11%)	5/47 (11%)	3/47 (6%)	3/47 (6%)
POLY-3 RATE (b)	5/41.36	5/45.36	3/42.76	3/43.51
POLY-3 PERCENT (g)	12.1%	11%	7%	6.9%
TERMINAL (d)	5/35 (14%)	5/41 (12%)	2/33 (6%)	2/35 (6%)
FIRST INCIDENCE	729 (T)	729 (T)	698	513

STATISTICAL TESTS

POLY 3	P=0.256N	P=0.571N	P=0.338N	P=0.328N
POLY 1.5	P=0.260N	P=0.595N	P=0.348N	P=0.339N
POLY 6	P=0.254N	P=0.544N	P=0.326N	P=0.316N
COCH-ARM / FISHERS	P=0.265N	P=0.630N	P=0.357N	P=0.357N
MAX-ISO-POLY-3	P=0.346N	P=0.440N	P=0.219N	P=0.214N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mandibular
 Pigmentation**

LESION RATES

OVERALL (a)	1/47 (2%)	0/47 (0%)	0/47 (0%)	1/47 (2%)
POLY-3 RATE (b)	1/41.36	0/45.36	0/42.64	1/42.86
POLY-3 PERCENT (g)	2.4%	0%	0%	2.3%
TERMINAL (d)	1/35 (3%)	0/41 (0%)	0/33 (0%)	1/35 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.566	P=0.482N	P=0.494N	P=0.753N
POLY 1.5	P=0.570	P=0.489N	P=0.497N	P=0.756N
POLY 6	P=0.562	P=0.473N	P=0.490N	P=0.749N
COCH-ARM / FISHERS	P=0.575	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.399N	P=0.158N	P=0.158N	P=0.489N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Angiectasis**

LESION RATES

OVERALL (a)	0/49 (0%)	0/49 (0%)	2/49 (4%)	0/45 (0%)
POLY-3 RATE (b)	0/42.63	0/47.82	2/43.64	0/40.81
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	2/34 (6%)	0/34 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.705	(e)	P=0.242	(e)
POLY 1.5	P=0.705	(e)	P=0.239	(e)
POLY 6	P=0.706	(e)	P=0.246	(e)
COCH-ARM / FISHERS	P=0.702	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.252	(e)	P=0.081	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Atrophy**

LESION RATES

OVERALL (a)	0/49 (0%)	4/49 (8%)	6/49 (12%)	0/45 (0%)
POLY-3 RATE (b)	0/42.63	4/47.82	6/44.52	0/40.81
POLY-3 PERCENT (g)	0%	8.4%	13.5%	0%
TERMINAL (d)	0/36 (0%)	4/44 (9%)	1/34 (3%)	0/34 (0%)
FIRST INCIDENCE	---	729 (T)	620	---

STATISTICAL TESTS

POLY 3	P=0.346N	P=0.077	P=0.017*	(e)
POLY 1.5	P=0.355N	P=0.070	P=0.016*	(e)
POLY 6	P=0.336N	P=0.085	P=0.019*	(e)
COCH-ARM / FISHERS	P=0.370N	P=0.059	P=0.013*	(e)
MAX-ISO-POLY-3	P=0.108	P=0.033*	P=0.006**	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	4/49 (8%)	4/49 (8%)	6/49 (12%)	2/45 (4%)
POLY-3 RATE (b)	4/42.63	4/47.82	6/44.56	2/40.81
POLY-3 PERCENT (g)	9.4%	8.4%	13.5%	4.9%
TERMINAL (d)	4/36 (11%)	4/44 (9%)	3/34 (9%)	2/34 (6%)
FIRST INCIDENCE	729 (T)	729 (T)	613	729 (T)

STATISTICAL TESTS

POLY 3	P=0.309N	P=0.579N	P=0.397	P=0.357N
POLY 1.5	P=0.309N	P=0.605N	P=0.382	P=0.365N
POLY 6	P=0.308N	P=0.549N	P=0.419	P=0.347N
COCH-ARM / FISHERS	P=0.310N	P=0.643N	P=0.370	P=0.380N
MAX-ISO-POLY-3	P=0.319N	P=0.435N	P=0.281	P=0.216N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node, Mesenteric Hemorrhage

LESION RATES

OVERALL (a)	4/49 (8%)	4/49 (8%)	7/49 (14%)	2/45 (4%)
POLY-3 RATE (b)	4/42.92	4/47.82	7/44.49	2/41.52
POLY-3 PERCENT (g)	9.3%	8.4%	15.7%	4.8%
TERMINAL (d)	3/36 (8%)	4/44 (9%)	5/34 (15%)	1/34 (3%)
FIRST INCIDENCE	650	729 (T)	472	485

STATISTICAL TESTS

POLY 3	P=0.307N	P=0.583N	P=0.281	P=0.352N
POLY 1.5	P=0.310N	P=0.607N	P=0.270	P=0.362N
POLY 6	P=0.304N	P=0.556N	P=0.293	P=0.342N
COCH-ARM / FISHERS	P=0.317N	P=0.643N	P=0.262	P=0.380N
MAX-ISO-POLY-3	P=0.271N	P=0.439N	P=0.188	P=0.213N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	2/49 (4%)	5/49 (10%)	1/49 (2%)	4/45 (9%)
POLY-3 RATE (b)	2/42.63	5/48.10	1/44.24	4/40.81
POLY-3 PERCENT (g)	4.7%	10.4%	2.3%	9.8%
TERMINAL (d)	2/36 (6%)	4/44 (9%)	0/34 (0%)	4/34 (12%)
FIRST INCIDENCE	729 (T)	652	540	729 (T)

STATISTICAL TESTS

POLY 3	P=0.369	P=0.268	P=0.487N	P=0.316
POLY 1.5	P=0.365	P=0.247	P=0.494N	P=0.309
POLY 6	P=0.374	P=0.295	P=0.478N	P=0.326
COCH-ARM / FISHERS	P=0.358	P=0.218	P=0.500N	P=0.299
MAX-ISO-POLY-3	P=0.293	P=0.171	P=0.273N	P=0.184

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

	Males			
DOSE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Lymph Node: Iliac
 Hematopoietic Cell Proliferation

LESION RATES

OVERALL (a)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/1.53	0/1.00	0/0.04	0/2.80
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mesentery
 Hemorrhage**

LESION RATES

OVERALL (a)	2/5 (40%)	0/8 (0%)	0/4 (0%)	0/5 (0%)
POLY-3 RATE (b)	2/5.00	0/7.11	0/3.62	0/4.52
POLY-3 PERCENT (g)	40%	0%	0%	0%
TERMINAL (d)	2/5 (40%)	0/6 (0%)	0/2 (0%)	0/2 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.139N	P=0.123N	P=0.291N	P=0.232N
POLY 1.5	P=0.146N	P=0.114N	P=0.278N	P=0.220N
POLY 6	P=0.133N	P=0.138N	P=0.316N	P=0.254N
COCH-ARM / FISHERS	P=0.182N	P=0.128N	P=0.278N	P=0.222N
MAX-ISO-POLY-3	P=0.021N*	P=0.028N*	P=0.108N	P=0.070N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mesentery: Fat
 Necrosis**

LESION RATES

OVERALL (a)	4/5 (80%)	7/8 (88%)	2/4 (50%)	4/5 (80%)
POLY-3 RATE (b)	4/5.00	7/7.54	2/3.74	4/5.00
POLY-3 PERCENT (g)	80%	92.9%	53.5%	80%
TERMINAL (d)	4/5 (80%)	6/6 (100%)	1/2 (50%)	1/2 (50%)
FIRST INCIDENCE	729 (T)	606	698	638

STATISTICAL TESTS

POLY 3	P=0.570N	P=0.581	P=0.462N	P=0.760
POLY 1.5	P=0.578N	P=0.617	P=0.438N	P=0.760
POLY 6	P=0.559N	P=0.519	P=0.505N	P=0.760
COCH-ARM / FISHERS	P=0.591N	P=0.641	P=0.405N	P=0.778N
MAX-ISO-POLY-3	P=0.358N	P=0.261	P=0.235N	P=1.000

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Nose
 Foreign Body

LESION RATES

OVERALL (a)	4/50 (8%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	4/43.30	0/47.36	0/43.33	0/45.17
POLY-3 PERCENT (g)	9.2%	0%	0%	0%
TERMINAL (d)	4/36 (11%)	0/43 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.043N*	P=0.050N*	P=0.060N	P=0.055N
POLY 1.5	P=0.040N*	P=0.055N	P=0.062N	P=0.057N
POLY 6	P=0.046N*	P=0.044N*	P=0.057N	P=0.052N
COCH-ARM / FISHERS	P=0.040N*	P=0.061N	P=0.061N	P=0.059N
MAX-ISO-POLY-3	P=0.003N**	P=0.020N*	P=0.020N*	P=0.019N*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Nose
 Inflammation Chronic**

LESION RATES

OVERALL (a)	5/50 (10%)	4/49 (8%)	4/49 (8%)	3/50 (6%)
POLY-3 RATE (b)	5/43.30	4/47.36	4/43.42	3/45.17
POLY-3 PERCENT (g)	11.6%	8.5%	9.2%	6.6%
TERMINAL (d)	5/36 (14%)	4/43 (9%)	3/34 (9%)	3/37 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	708	729 (T)

STATISTICAL TESTS

POLY 3	P=0.311N	P=0.444N	P=0.498N	P=0.333N
POLY 1.5	P=0.311N	P=0.472N	P=0.508N	P=0.343N
POLY 6	P=0.312N	P=0.413N	P=0.486N	P=0.321N
COCH-ARM / FISHERS	P=0.310N	P=0.513N	P=0.513N	P=0.357N
MAX-ISO-POLY-3	P=0.353N	P=0.320N	P=0.361N	P=0.217N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/43.30	2/48.36	0/44.32	0/44.33
POLY-3 PERCENT (g)	2.3%	4.1%	0%	0%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.214N	P=0.538	P=0.495N	P=0.495N
POLY 1.5	P=0.217N	P=0.523	P=0.498N	P=0.499N
POLY 6	P=0.210N	P=0.556	P=0.492N	P=0.491N
COCH-ARM / FISHERS	P=0.222N	P=0.500	P=0.500N	P=0.505N
MAX-ISO-POLY-3	P=0.196N	P=0.322	P=0.158N	P=0.160N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/44.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pancreas: Acinus
 Cytoplasmic Alteration**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	1/43.30	3/48.36	2/44.44	0/44.33
POLY-3 PERCENT (g)	2.3%	6.2%	4.5%	0%
TERMINAL (d)	1/36 (3%)	3/44 (7%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	698	---

STATISTICAL TESTS

POLY 3	P=0.212N	P=0.346	P=0.509	P=0.495N
POLY 1.5	P=0.217N	P=0.330	P=0.503	P=0.499N
POLY 6	P=0.206N	P=0.366	P=0.516	P=0.491N
COCH-ARM / FISHERS	P=0.224N	P=0.309	P=0.500	P=0.505N
MAX-ISO-POLY-3	P=0.213N	P=0.196	P=0.291	P=0.160N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Parathyroid Gland
 Cyst**

LESION RATES

OVERALL (a)	1/48 (2%)	0/48 (0%)	0/47 (0%)	1/46 (2%)
POLY-3 RATE (b)	1/41.85	0/46.36	0/41.58	1/41.86
POLY-3 PERCENT (g)	2.4%	0%	0%	2.4%
TERMINAL (d)	1/35 (3%)	0/42 (0%)	0/32 (0%)	1/34 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.557	P=0.480N	P=0.501N	P=0.761N
POLY 1.5	P=0.561	P=0.488N	P=0.504N	P=0.757
POLY 6	P=0.552	P=0.470N	P=0.498N	P=0.757N
COCH-ARM / FISHERS	P=0.566	P=0.500N	P=0.505N	P=0.742
MAX-ISO-POLY-3	P=0.404N	P=0.158N	P=0.160N	P=0.499N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Peripheral Nerve
 Atrophy**

LESION RATES

OVERALL (a)	0/1 (0%)	1/1 (100%)	2/4 (50%)	1/3 (33%)
POLY-3 RATE (b)	0/1.00	1/1.00	2/3.08	1/2.14
POLY-3 PERCENT (g)	0%	100%	64.9%	46.7%
TERMINAL (d)	0/1 (0%)	1/1 (100%)	0/1 (0%)	1/1 (100%)
FIRST INCIDENCE	---	729 (T)	701	729 (T)

STATISTICAL TESTS

POLY 3	P=0.656	(e)	P=0.509	P=0.659
POLY 1.5	P=0.684N	(e)	P=0.530	P=0.675
POLY 6	P=0.558	(e)	P=0.501	P=0.635
COCH-ARM / FISHERS	P=0.624N	P=0.500	P=0.600	P=0.750
MAX-ISO-POLY-3	P=0.272	P<0.001**	P=0.172	P=0.258

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/47.36	0/43.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/43 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Cyst**

LESION RATES

OVERALL (a)	4/50 (8%)	2/49 (4%)	4/49 (8%)	3/50 (6%)
POLY-3 RATE (b)	4/43.63	2/47.36	4/43.55	3/45.17
POLY-3 PERCENT (g)	9.2%	4.2%	9.2%	6.6%
TERMINAL (d)	3/36 (8%)	2/43 (5%)	3/34 (9%)	3/37 (8%)
FIRST INCIDENCE	636	729 (T)	673	729 (T)

STATISTICAL TESTS

POLY 3	P=0.536N	P=0.300N	P=0.643	P=0.481N
POLY 1.5	P=0.532N	P=0.318N	P=0.635	P=0.489N
POLY 6	P=0.542N	P=0.281N	P=0.636N	P=0.473N
COCH-ARM / FISHERS	P=0.526N	P=0.349N	P=0.631	P=0.500N
MAX-ISO-POLY-3	P=0.519N	P=0.183N	P=0.498	P=0.333N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	1/50 (2%)	0/49 (0%)	0/49 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.30	0/47.36	0/43.33	1/45.17
POLY-3 PERCENT (g)	2.3%	0%	0%	2.2%
TERMINAL (d)	1/36 (3%)	0/43 (0%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.566	P=0.482N	P=0.500N	P=0.751N
POLY 1.5	P=0.570	P=0.491N	P=0.503N	P=0.755N
POLY 6	P=0.561	P=0.472N	P=0.496N	P=0.746N
COCH-ARM / FISHERS	P=0.577	P=0.505N	P=0.505N	P=0.753N
MAX-ISO-POLY-3	P=0.401N	P=0.160N	P=0.160N	P=0.487N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Preputial Gland
 Cyst**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	1/43.30	2/48.36	0/44.32	4/45.17
POLY-3 PERCENT (g)	2.3%	4.1%	0%	8.9%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	0/34 (0%)	4/37 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.091	P=0.538	P=0.495N	P=0.191
POLY 1.5	P=0.091	P=0.523	P=0.498N	P=0.186
POLY 6	P=0.091	P=0.556	P=0.492N	P=0.198
COCH-ARM / FISHERS	P=0.091	P=0.500	P=0.500N	P=0.181
MAX-ISO-POLY-3	P=0.090	P=0.322	P=0.158N	P=0.096

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Preputial Gland
 Inflammation Chronic**

LESION RATES

OVERALL (a)	7/50 (14%)	4/50 (8%)	3/50 (6%)	7/50 (14%)
POLY-3 RATE (b)	7/43.90	4/48.36	3/44.44	7/45.17
POLY-3 PERCENT (g)	15.9%	8.3%	6.8%	15.5%
TERMINAL (d)	6/36 (17%)	4/44 (9%)	2/34 (6%)	7/37 (19%)
FIRST INCIDENCE	534	729 (T)	698	729 (T)

STATISTICAL TESTS

POLY 3	P=0.412	P=0.209N	P=0.151N	P=0.592N
POLY 1.5	P=0.418	P=0.229N	P=0.157N	P=0.600N
POLY 6	P=0.404	P=0.186N	P=0.145N	P=0.581N
COCH-ARM / FISHERS	P=0.427	P=0.262N	P=0.159N	P=0.613N
MAX-ISO-POLY-3	P=0.326N	P=0.140N	P=0.087N	P=0.476N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Prostate
 Inflammation Chronic**

LESION RATES

OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/43.85	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	6.8%	0%	0%	0%
TERMINAL (d)	2/36 (6%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	556	---	---	---

STATISTICAL TESTS

POLY 3	P=0.087N	P=0.102N	P=0.117N	P=0.113N
POLY 1.5	P=0.083N	P=0.109N	P=0.119N	P=0.116N
POLY 6	P=0.091N	P=0.095N	P=0.114N	P=0.111N
COCH-ARM / FISHERS	P=0.081N	P=0.121N	P=0.121N	P=0.121N
MAX-ISO-POLY-3	P=0.009N**	P=0.038N*	P=0.038N*	P=0.038N*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Salivary Glands
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	2/50 (4%)	4/50 (8%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	2/43.30	4/48.36	3/44.44	6/45.17
POLY-3 PERCENT (g)	4.6%	8.3%	6.8%	13.3%
TERMINAL (d)	2/36 (6%)	4/44 (9%)	2/34 (6%)	6/37 (16%)
FIRST INCIDENCE	729 (T)	729 (T)	698	729 (T)

STATISTICAL TESTS

POLY 3	P=0.114	P=0.390	P=0.512	P=0.146
POLY 1.5	P=0.113	P=0.369	P=0.504	P=0.141
POLY 6	P=0.115	P=0.415	P=0.522	P=0.153
COCH-ARM / FISHERS	P=0.111	P=0.339	P=0.500	P=0.134
MAX-ISO-POLY-3	P=0.121	P=0.254	P=0.336	P=0.081

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Salivary Glands: Submandibular Gland
Cytoplasmic Alteration**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Skin
 Ulcer

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.30	2/48.36	0/44.32	1/45.17
POLY-3 PERCENT (g)	0%	4.1%	0%	2.2%
TERMINAL (d)	0/36 (0%)	2/44 (5%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.581	P=0.263	(e)	P=0.508
POLY 1.5	P=0.573	P=0.252	(e)	P=0.505
POLY 6	P=0.590	P=0.275	(e)	P=0.513
COCH-ARM / FISHERS	P=0.562	P=0.247	(e)	P=0.500
MAX-ISO-POLY-3	P=0.348	P=0.100	(e)	P=0.169

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	23/50 (46%)	25/50 (50%)	28/50 (56%)	28/50 (56%)
POLY-3 RATE (b)	23/46.81	25/49.58	28/48.76	28/49.06
POLY-3 PERCENT (g)	49.1%	50.4%	57.4%	57.1%
TERMINAL (d)	14/36 (39%)	20/44 (46%)	16/34 (47%)	18/37 (49%)
FIRST INCIDENCE	534	593	256	485

STATISTICAL TESTS

POLY 3	P=0.238	P=0.531	P=0.272	P=0.283
POLY 1.5	P=0.222	P=0.491	P=0.245	P=0.257
POLY 6	P=0.248	P=0.566	P=0.299	P=0.305
COCH-ARM / FISHERS	P=0.192	P=0.421	P=0.212	P=0.212
MAX-ISO-POLY-3	P=0.357	P=0.450	P=0.213	P=0.224

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen: Lymphoid Follicle
 Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	1/48.39	4/45.41	0/45.17
POLY-3 PERCENT (g)	0%	2.1%	8.8%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	721	620	---

STATISTICAL TESTS

POLY 3	P=0.540N	P=0.522	P=0.066	(e)
POLY 1.5	P=0.544N	P=0.513	P=0.063	(e)
POLY 6	P=0.537N	P=0.532	P=0.072	(e)
COCH-ARM / FISHERS	P=0.548N	P=0.500	P=0.059	(e)
MAX-ISO-POLY-3	P=0.171	P=0.186	P=0.024*	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen: Lymphoid Follicle
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.30	1/48.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	0%	2.1%	2.3%	2.2%
TERMINAL (d)	0/36 (0%)	1/44 (2%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.448	P=0.522	P=0.505	P=0.508
POLY 1.5	P=0.445	P=0.513	P=0.502	P=0.505
POLY 6	P=0.453	P=0.532	P=0.508	P=0.513
COCH-ARM / FISHERS	P=0.438	P=0.500	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.347	P=0.185	P=0.164	P=0.169

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/49 (2%)	5/50 (10%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.71	5/48.78	1/44.32	2/45.32
POLY-3 PERCENT (g)	2.3%	10.3%	2.3%	4.4%
TERMINAL (d)	1/36 (3%)	4/44 (9%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	606	729 (T)	690

STATISTICAL TESTS

POLY 3	P=0.509N	P=0.136	P=0.753N	P=0.521
POLY 1.5	P=0.517N	P=0.123	P=0.755N	P=0.515
POLY 6	P=0.500N	P=0.151	P=0.750N	P=0.528
COCH-ARM / FISHERS	P=0.530N	P=0.107	P=0.747N	P=0.508
MAX-ISO-POLY-3	P=0.383	P=0.075	P=0.489N	P=0.302

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Cyst**

LESION RATES

OVERALL (a)	0/49 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.71	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular
 Erosion**

LESION RATES

OVERALL (a)	0/49 (0%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/42.71	0/48.36	2/45.29	1/45.47
POLY-3 PERCENT (g)	0%	0%	4.4%	2.2%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	256	648

STATISTICAL TESTS

POLY 3	P=0.325	(e)	P=0.250	P=0.512
POLY 1.5	P=0.324	(e)	P=0.247	P=0.509
POLY 6	P=0.326	(e)	P=0.254	P=0.517
COCH-ARM / FISHERS	P=0.324	(e)	P=0.253	P=0.505
MAX-ISO-POLY-3	P=0.193	(e)	P=0.088	P=0.173

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Glandular: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/49 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/42.71	2/48.39	0/44.32	0/45.17
POLY-3 PERCENT (g)	2.3%	4.1%	0%	0%
TERMINAL (d)	1/36 (3%)	1/44 (2%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	721	---	---

STATISTICAL TESTS

POLY 3	P=0.209N	P=0.543	P=0.493N	P=0.489N
POLY 1.5	P=0.211N	P=0.529	P=0.495N	P=0.492N
POLY 6	P=0.206N	P=0.559	P=0.490N	P=0.486N
COCH-ARM / FISHERS	P=0.216N	P=0.508	P=0.495N	P=0.495N
MAX-ISO-POLY-3	P=0.195N	P=0.327	P=0.157N	P=0.157N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Testes: Germinal Epithelium
 Atrophy

LESION RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	2/43.90	2/48.36	4/44.66	2/45.17
POLY-3 PERCENT (g)	4.6%	4.1%	9%	4.4%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	2/34 (6%)	2/37 (5%)
FIRST INCIDENCE	534	729 (T)	639	729 (T)

STATISTICAL TESTS

POLY 3	P=0.599	P=0.658N	P=0.345	P=0.684N
POLY 1.5	P=0.600	P=0.673N	P=0.339	P=0.688N
POLY 6	P=0.597	P=0.642N	P=0.353	P=0.679N
COCH-ARM / FISHERS	P=0.603	P=0.691N	P=0.339	P=0.691N
MAX-ISO-POLY-3	P=0.508	P=0.462N	P=0.208	P=0.488N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thymus
 Atrophy**

LESION RATES

OVERALL (a)	4/45 (9%)	5/46 (11%)	13/42 (31%)	8/45 (18%)
POLY-3 RATE (b)	4/40.94	5/45.28	13/39.53	8/43.23
POLY-3 PERCENT (g)	9.8%	11%	32.9%	18.5%
TERMINAL (d)	0/33 (0%)	3/41 (7%)	2/28 (7%)	1/33 (3%)
FIRST INCIDENCE	556	593	472	493

STATISTICAL TESTS

POLY 3	P=0.167	P=0.563	P=0.010**	P=0.203
POLY 1.5	P=0.159	P=0.544	P=0.009**	P=0.192
POLY 6	P=0.176	P=0.582	P=0.012*	P=0.215
COCH-ARM / FISHERS	P=0.152	P=0.514	P=0.009**	P=0.176
MAX-ISO-POLY-3	P=0.051	P=0.426	P=0.004**	P=0.133

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thymus
 Cyst**

LESION RATES

OVERALL (a)	0/45 (0%)	2/46 (4%)	0/42 (0%)	5/45 (11%)
POLY-3 RATE (b)	0/39.19	2/44.41	0/36.78	5/42.15
POLY-3 PERCENT (g)	0%	4.5%	0%	11.9%
TERMINAL (d)	0/33 (0%)	1/41 (2%)	0/28 (0%)	2/33 (6%)
FIRST INCIDENCE	---	725	---	493

STATISTICAL TESTS

POLY 3	P=0.009**	P=0.266	(e)	P=0.036*
POLY 1.5	P=0.009**	P=0.256	(e)	P=0.034*
POLY 6	P=0.010**	P=0.277	(e)	P=0.040*
COCH-ARM / FISHERS	P=0.009**	P=0.253	(e)	P=0.028*
MAX-ISO-POLY-3	P=0.008**	P=0.102	(e)	P=0.014*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thymus
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/45 (0%)	2/46 (4%)	1/42 (2%)	0/45 (0%)
POLY-3 RATE (b)	0/39.19	2/44.39	1/36.78	0/40.65
POLY-3 PERCENT (g)	0%	4.5%	2.7%	0%
TERMINAL (d)	0/33 (0%)	2/41 (5%)	1/28 (4%)	0/33 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.424N	P=0.266	P=0.487	(e)
POLY 1.5	P=0.431N	P=0.256	P=0.485	(e)
POLY 6	P=0.417N	P=0.277	P=0.490	(e)
COCH-ARM / FISHERS	P=0.441N	P=0.253	P=0.483	(e)
MAX-ISO-POLY-3	P=0.343N	P=0.102	P=0.154	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicle
 Degeneration Focal**

LESION RATES

OVERALL (a)	12/50 (24%)	8/50 (16%)	9/50 (18%)	9/50 (18%)
POLY-3 RATE (b)	12/44.35	8/48.85	9/44.86	9/46.38
POLY-3 PERCENT (g)	27.1%	16.4%	20.1%	19.4%
TERMINAL (d)	9/36 (25%)	6/44 (14%)	6/34 (18%)	7/37 (19%)
FIRST INCIDENCE	590	593	660	513

STATISTICAL TESTS

POLY 3	P=0.367N	P=0.158N	P=0.298N	P=0.269N
POLY 1.5	P=0.366N	P=0.183N	P=0.309N	P=0.286N
POLY 6	P=0.371N	P=0.134N	P=0.286N	P=0.254N
COCH-ARM / FISHERS	P=0.368N	P=0.227N	P=0.312N	P=0.312N
MAX-ISO-POLY-3	P=0.268N	P=0.115N	P=0.220N	P=0.199N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	2/45.17
POLY-3 PERCENT (g)	0%	0%	0%	4.4%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	2/37 (5%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.042*	(e)	(e)	P=0.247
POLY 1.5	P=0.042*	(e)	(e)	P=0.243
POLY 6	P=0.042*	(e)	(e)	P=0.251
COCH-ARM / FISHERS	P=0.044*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.040*	(e)	(e)	P=0.085

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Urinary Bladder
Infiltration Cellular Lymphocyte

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---

.....
STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

.....

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Urinary Bladder: Transitional Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.30	1/48.36	2/44.44	0/45.17
POLY-3 PERCENT (g)	0%	2.1%	4.5%	0%
TERMINAL (d)	0/36 (0%)	1/44 (2%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	698	---

STATISTICAL TESTS

POLY 3	P=0.552N	P=0.522	P=0.243	(e)
POLY 1.5	P=0.556N	P=0.513	P=0.239	(e)
POLY 6	P=0.547N	P=0.532	P=0.248	(e)
COCH-ARM / FISHERS	P=0.562N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.345	P=0.185	P=0.081	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Cortex
 Accessory Adrenal Cortical Nodule**

LESION RATES

OVERALL (a)	3/50 (6%)	7/50 (14%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	3/44.49	7/45.74	5/44.97	3/46.24
POLY-3 PERCENT (g)	6.7%	15.3%	11.1%	6.5%
TERMINAL (d)	2/35 (6%)	7/40 (18%)	5/40 (13%)	2/40 (5%)
FIRST INCIDENCE	565	729 (T)	729 (T)	577

STATISTICAL TESTS

POLY 3	P=0.271N	P=0.168	P=0.362	P=0.644N
POLY 1.5	P=0.282N	P=0.166	P=0.359	P=0.653N
POLY 6	P=0.256N	P=0.173	P=0.368	P=0.632N
COCH-ARM / FISHERS	P=0.292N	P=0.159	P=0.357	P=0.661N
MAX-ISO-POLY-3	P=0.386N	P=0.100	P=0.237	P=0.480N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Cortex
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.96	1/45.74	0/44.97	1/45.74
POLY-3 PERCENT (g)	2.3%	2.2%	0%	2.2%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.665	P=0.752N	P=0.495N	P=0.752N
POLY 1.5	P=0.662	P=0.755N	P=0.498N	P=0.756N
POLY 6	P=0.670	P=0.748N	P=0.492N	P=0.746N
COCH-ARM / FISHERS	P=0.661	P=0.753N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.535N	P=0.488N	P=0.158N	P=0.488N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Cortex
 Hypertrophy Focal**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/45.74	0/44.97	1/45.74
POLY-3 PERCENT (g)	0%	2.2%	0%	2.2%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	---	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.495	P=0.508	(e)	P=0.508
POLY 1.5	P=0.491	P=0.505	(e)	P=0.504
POLY 6	P=0.501	P=0.512	(e)	P=0.513
COCH-ARM / FISHERS	P=0.486	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.277	P=0.168	(e)	P=0.168

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Cortex: Capsule
Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Medulla
 Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	4/43.96	1/45.74	1/44.97	1/45.74
POLY-3 PERCENT (g)	9.1%	2.2%	2.2%	2.2%
TERMINAL (d)	4/35 (11%)	1/40 (3%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.306N	P=0.167N	P=0.172N	P=0.167N
POLY 1.5	P=0.308N	P=0.171N	P=0.175N	P=0.173N
POLY 6	P=0.304N	P=0.161N	P=0.166N	P=0.158N
COCH-ARM / FISHERS	P=0.307N	P=0.181N	P=0.181N	P=0.181N
MAX-ISO-POLY-3	P=0.080N	P=0.080N	P=0.082N	P=0.080N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Bone Marrow
 Hyperplasia**

LESION RATES

OVERALL (a)	14/50 (28%)	18/49 (37%)	23/50 (46%)	11/50 (22%)
POLY-3 RATE (b)	14/45.72	18/48.04	23/48.14	11/46.55
POLY-3 PERCENT (g)	30.6%	37.5%	47.8%	23.6%
TERMINAL (d)	6/35 (17%)	12/40 (30%)	16/40 (40%)	10/40 (25%)
FIRST INCIDENCE	565	456	442	420

STATISTICAL TESTS

POLY 3	P=0.082N	P=0.316	P=0.066	P=0.302N
POLY 1.5	P=0.080N	P=0.291	P=0.057	P=0.309N
POLY 6	P=0.086N	P=0.336	P=0.076	P=0.299N
COCH-ARM / FISHERS	P=0.078N	P=0.238	P=0.048*	P=0.322N
MAX-ISO-POLY-3	P=0.108N	P=0.250	P=0.046*	P=0.228N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Bone
 Fibrosis**

LESION RATES

OVERALL (a)	3/50 (6%)	4/50 (8%)	4/50 (8%)	5/50 (10%)
POLY-3 RATE (b)	3/43.96	4/45.74	4/44.97	5/45.74
POLY-3 PERCENT (g)	6.8%	8.8%	8.9%	10.9%
TERMINAL (d)	3/35 (9%)	4/40 (10%)	4/40 (10%)	5/40 (13%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.365	P=0.522	P=0.512	P=0.378
POLY 1.5	P=0.357	P=0.514	P=0.506	P=0.368
POLY 6	P=0.378	P=0.532	P=0.522	P=0.394
COCH-ARM / FISHERS	P=0.350	P=0.500	P=0.500	P=0.357
MAX-ISO-POLY-3	P=0.412	P=0.369	P=0.360	P=0.253

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Bone: Cranium
 Osteopetrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Brain
 Compression**

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/43.96	0/45.12	1/44.97	2/45.74
POLY-3 PERCENT (g)	0%	0%	2.2%	4.4%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	2/40 (5%)
FIRST INCIDENCE	---	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.110	(e)	P=0.505	P=0.246
POLY 1.5	P=0.108	(e)	P=0.502	P=0.242
POLY 6	P=0.113	(e)	P=0.508	P=0.252
COCH-ARM / FISHERS	P=0.107	(e)	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.095	(e)	P=0.164	P=0.085

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Clitoral Gland
 Hyperplasia**

LESION RATES

OVERALL (a)	0/47 (0%)	2/47 (4%)	13/49 (27%)	41/50 (82%)
POLY-3 RATE (b)	0/40.96	2/43.87	13/44.27	41/48.43
POLY-3 PERCENT (g)	0%	4.6%	29.4%	84.7%
TERMINAL (d)	0/32 (0%)	1/38 (3%)	12/39 (31%)	35/40 (88%)
FIRST INCIDENCE	---	622	646	158

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.253	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.247	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.260	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.247	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.091	P<0.001**	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Clitoral Gland: Duct
 Dilatation**

LESION RATES

OVERALL (a)	0/47 (0%)	2/47 (4%)	17/49 (35%)	49/50 (98%)
POLY-3 RATE (b)	0/40.96	2/43.49	17/43.97	49/50.00
POLY-3 PERCENT (g)	0%	4.6%	38.7%	98%
TERMINAL (d)	0/32 (0%)	2/38 (5%)	17/39 (44%)	39/40 (98%)
FIRST INCIDENCE	---	729 (T)	729 (T)	158

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.251	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.246	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.256	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.247	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.089	P<0.001**	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Eye
 Cataract**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	2/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.618N	(e)	P=0.242	(e)
POLY 1.5	P=0.622N	(e)	P=0.240	(e)
POLY 6	P=0.612N	(e)	P=0.246	(e)
COCH-ARM / FISHERS	P=0.624N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.270	(e)	P=0.081	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Eye
 Inflammation Chronic**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/43.96	0/45.74	2/44.97	1/45.74
POLY-3 PERCENT (g)	4.6%	0%	4.5%	2.2%
TERMINAL (d)	2/35 (6%)	0/40 (0%)	2/40 (5%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.607N	P=0.228N	P=0.686N	P=0.486N
POLY 1.5	P=0.610N	P=0.231N	P=0.690N	P=0.493N
POLY 6	P=0.603N	P=0.224N	P=0.680N	P=0.477N
COCH-ARM / FISHERS	P=0.610N	P=0.247N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.412N	P=0.076N	P=0.490N	P=0.273N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Eye: Cornea
 Hyperplasia

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.96	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	4.6%	0%	2.2%	0%
TERMINAL (d)	2/35 (6%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.319N	P=0.228N	P=0.492N	P=0.228N
POLY 1.5	P=0.320N	P=0.231N	P=0.496N	P=0.233N
POLY 6	P=0.318N	P=0.224N	P=0.486N	P=0.222N
COCH-ARM / FISHERS	P=0.318N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.082N	P=0.076N	P=0.276N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Harderian Gland
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.96	2/45.74	1/44.97	1/45.74
POLY-3 PERCENT (g)	2.3%	4.4%	2.2%	2.2%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.548N	P=0.514	P=0.756N	P=0.752N
POLY 1.5	P=0.553N	P=0.509	P=0.758N	P=0.756N
POLY 6	P=0.541N	P=0.520	P=0.752N	P=0.746N
COCH-ARM / FISHERS	P=0.558N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.586N	P=0.296	P=0.493N	P=0.488N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Heart
 Cardiomyopathy**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/43.96	2/45.74	0/44.97	2/45.74
POLY-3 PERCENT (g)	2.3%	4.4%	0%	4.4%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	2/40 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.452	P=0.514	P=0.495N	P=0.514
POLY 1.5	P=0.447	P=0.509	P=0.498N	P=0.507
POLY 6	P=0.459	P=0.520	P=0.492N	P=0.523
COCH-ARM / FISHERS	P=0.442	P=0.500	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.443	P=0.296	P=0.158N	P=0.296

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Islets, Pancreatic
 Hyperplasia**

LESION RATES

OVERALL (a)	1/49 (2%)	1/50 (2%)	1/49 (2%)	0/48 (0%)
POLY-3 RATE (b)	1/43.53	1/45.74	1/44.63	0/44.57
POLY-3 PERCENT (g)	2.3%	2.2%	2.2%	0%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.340N	P=0.750N	P=0.755N	P=0.495N
POLY 1.5	P=0.343N	P=0.751N	P=0.758N	P=0.499N
POLY 6	P=0.335N	P=0.747N	P=0.752N	P=0.490N
COCH-ARM / FISHERS	P=0.345N	P=0.747N	P=0.753N	P=0.505N
MAX-ISO-POLY-3	P=0.339N	P=0.486N	P=0.492N	P=0.160N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Cyst**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/45.74	1/44.97	1/45.74
POLY-3 PERCENT (g)	0%	2.2%	2.2%	2.2%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.562	P=0.508	P=0.505	P=0.508
POLY 1.5	P=0.556	P=0.505	P=0.502	P=0.504
POLY 6	P=0.570	P=0.512	P=0.508	P=0.513
COCH-ARM / FISHERS	P=0.551	P=0.500	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.351	P=0.168	P=0.164	P=0.168

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Glomerulosclerosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	3/47.05	0/45.74
POLY-3 PERCENT (g)	0%	0%	6.4%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	152	---

STATISTICAL TESTS

POLY 3	P=0.528N	(e)	P=0.131	(e)
POLY 1.5	P=0.535N	(e)	P=0.127	(e)
POLY 6	P=0.519N	(e)	P=0.137	(e)
COCH-ARM / FISHERS	P=0.540N	(e)	P=0.121	(e)
MAX-ISO-POLY-3	P=0.195	(e)	P=0.049*	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Hydronephrosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	1/45.74
POLY-3 PERCENT (g)	0%	0%	0%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	---	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.240	(e)	(e)	P=0.508
POLY 1.5	P=0.238	(e)	(e)	P=0.504
POLY 6	P=0.243	(e)	(e)	P=0.513
COCH-ARM / FISHERS	P=0.237	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.144	(e)	(e)	P=0.168

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Infarct**

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	4/43.96	3/45.74	1/45.18	0/45.74
POLY-3 PERCENT (g)	9.1%	6.6%	2.2%	0%
TERMINAL (d)	4/35 (11%)	3/40 (8%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	672	---

STATISTICAL TESTS

POLY 3	P=0.056N	P=0.478N	P=0.170N	P=0.055N
POLY 1.5	P=0.057N	P=0.486N	P=0.175N	P=0.058N
POLY 6	P=0.054N	P=0.468N	P=0.164N	P=0.052N
COCH-ARM / FISHERS	P=0.059N	P=0.500N	P=0.181N	P=0.059N
MAX-ISO-POLY-3	P=0.034N*	P=0.331N	P=0.081N	P=0.019N*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	4/50 (8%)	4/50 (8%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	4/43.96	4/46.12	2/45.28	3/45.74
POLY-3 PERCENT (g)	9.1%	8.7%	4.4%	6.6%
TERMINAL (d)	4/35 (11%)	3/40 (8%)	1/40 (3%)	3/40 (8%)
FIRST INCIDENCE	729 (T)	622	643	729 (T)

STATISTICAL TESTS

POLY 3	P=0.472N	P=0.617N	P=0.323N	P=0.478N
POLY 1.5	P=0.477N	P=0.626N	P=0.331N	P=0.489N
POLY 6	P=0.465N	P=0.603N	P=0.313N	P=0.463N
COCH-ARM / FISHERS	P=0.480N	P=0.643N	P=0.339N	P=0.500N
MAX-ISO-POLY-3	P=0.423N	P=0.471N	P=0.193N	P=0.331N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Inflammation**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.14	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	4.5%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	681	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.319N	P=0.229N	P=0.494N	P=0.229N
POLY 1.5	P=0.320N	P=0.232N	P=0.497N	P=0.233N
POLY 6	P=0.318N	P=0.226N	P=0.489N	P=0.224N
COCH-ARM / FISHERS	P=0.318N	P=0.247N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.082N	P=0.076N	P=0.277N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Metaplasia Osseous**

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	1/43.96	2/45.74	0/44.97	3/46.15
POLY-3 PERCENT (g)	2.3%	4.4%	0%	6.5%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	2/40 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	---	611

STATISTICAL TESTS

POLY 3	P=0.210	P=0.514	P=0.495N	P=0.323
POLY 1.5	P=0.205	P=0.509	P=0.498N	P=0.314
POLY 6	P=0.217	P=0.520	P=0.492N	P=0.335
COCH-ARM / FISHERS	P=0.201	P=0.500	P=0.500N	P=0.309
MAX-ISO-POLY-3	P=0.223	P=0.296	P=0.158N	P=0.173

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Mineralization**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney
 Nephropathy**

LESION RATES

OVERALL (a)	13/50 (26%)	11/50 (22%)	13/50 (26%)	14/50 (28%)
POLY-3 RATE (b)	13/44.99	11/47.43	13/47.27	14/46.19
POLY-3 PERCENT (g)	28.9%	23.2%	27.5%	30.3%
TERMINAL (d)	9/35 (26%)	8/40 (20%)	9/40 (23%)	12/40 (30%)
FIRST INCIDENCE	625	446	152	611

STATISTICAL TESTS

POLY 3	P=0.362	P=0.349N	P=0.533N	P=0.533
POLY 1.5	P=0.358	P=0.366N	P=0.549N	P=0.517
POLY 6	P=0.372	P=0.335N	P=0.518N	P=0.552
COCH-ARM / FISHERS	P=0.370	P=0.408N	P=0.590N	P=0.500
MAX-ISO-POLY-3	P=0.519	P=0.272N	P=0.441N	P=0.441

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney: Glomerulus
 Metaplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	5/50 (10%)	27/50 (54%)
POLY-3 RATE (b)	2/43.96	1/45.74	5/44.97	27/46.24
POLY-3 PERCENT (g)	4.6%	2.2%	11.1%	58.4%
TERMINAL (d)	2/35 (6%)	1/40 (3%)	5/40 (13%)	26/40 (65%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	577

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.486N	P=0.225	P<0.001**
POLY 1.5	P<0.001**	P=0.491N	P=0.221	P<0.001**
POLY 6	P<0.001**	P=0.480N	P=0.232	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.218	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.273N	P=0.128	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.17	3/47.01	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	6.4%	0%	0%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	672	502	---	---

STATISTICAL TESTS

POLY 3	P=0.175N	P=0.328	P=0.496N	P=0.493N
POLY 1.5	P=0.179N	P=0.320	P=0.498N	P=0.496N
POLY 6	P=0.171N	P=0.337	P=0.494N	P=0.488N
COCH-ARM / FISHERS	P=0.185N	P=0.309	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.135N	P=0.177	P=0.158N	P=0.158N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/45.89	0/44.97	1/45.74
POLY-3 PERCENT (g)	0%	2.2%	0%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	---	689	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.495	P=0.509	(e)	P=0.508
POLY 1.5	P=0.491	P=0.506	(e)	P=0.504
POLY 6	P=0.501	P=0.513	(e)	P=0.513
COCH-ARM / FISHERS	P=0.486	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.277	P=0.169	(e)	P=0.168

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Kidney: Renal Tubule
 Pigmentation**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/45.74	0/44.97	1/45.78
POLY-3 PERCENT (g)	0%	2.2%	0%	2.2%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	729 (T)	---	718

STATISTICAL TESTS

POLY 3	P=0.495	P=0.508	(e)	P=0.508
POLY 1.5	P=0.491	P=0.505	(e)	P=0.504
POLY 6	P=0.502	P=0.512	(e)	P=0.514
COCH-ARM / FISHERS	P=0.486	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.277	P=0.168	(e)	P=0.169

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Basophilic Focus

LESION RATES

OVERALL (a)	0/50 (0%)	4/50 (8%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	4/45.74	3/45.57	0/45.74
POLY-3 PERCENT (g)	0%	8.8%	6.6%	0%
TERMINAL (d)	0/35 (0%)	4/40 (10%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	---	729 (T)	618	---

STATISTICAL TESTS

POLY 3	P=0.155N	P=0.065	P=0.125	(e)
POLY 1.5	P=0.160N	P=0.064	P=0.122	(e)
POLY 6	P=0.147N	P=0.068	P=0.130	(e)
COCH-ARM / FISHERS	P=0.169N	P=0.059	P=0.121	(e)
MAX-ISO-POLY-3	P=0.174N	P=0.023*	P=0.043*	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Clear Cell Focus

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	2/43.96	1/45.74	1/44.97	3/45.74
POLY-3 PERCENT (g)	4.6%	2.2%	2.2%	6.6%
TERMINAL (d)	2/35 (6%)	1/40 (3%)	1/40 (3%)	3/40 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.269	P=0.486N	P=0.492N	P=0.518
POLY 1.5	P=0.265	P=0.491N	P=0.496N	P=0.509
POLY 6	P=0.274	P=0.480N	P=0.486N	P=0.531
COCH-ARM / FISHERS	P=0.262	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.322	P=0.273N	P=0.276N	P=0.343

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
Cyst

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Eosinophilic Focus

LESION RATES

OVERALL (a)	9/50 (18%)	8/50 (16%)	11/50 (22%)	11/50 (22%)
POLY-3 RATE (b)	9/44.14	8/45.74	11/45.27	11/46.29
POLY-3 PERCENT (g)	20.4%	17.5%	24.3%	23.8%
TERMINAL (d)	8/35 (23%)	8/40 (20%)	10/40 (25%)	9/40 (23%)
FIRST INCIDENCE	681	729 (T)	646	577

STATISTICAL TESTS

POLY 3	P=0.356	P=0.468N	P=0.425	P=0.447
POLY 1.5	P=0.339	P=0.478N	P=0.413	P=0.425
POLY 6	P=0.381	P=0.454N	P=0.443	P=0.478
COCH-ARM / FISHERS	P=0.325	P=0.500N	P=0.402	P=0.402
MAX-ISO-POLY-3	P=0.456	P=0.365N	P=0.331	P=0.352

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	6/50 (12%)	2/50 (4%)	4/50 (8%)	3/50 (6%)
POLY-3 RATE (b)	6/44.89	2/46.49	4/45.44	3/45.74
POLY-3 PERCENT (g)	13.4%	4.3%	8.8%	6.6%
TERMINAL (d)	3/35 (9%)	1/40 (3%)	2/40 (5%)	3/40 (8%)
FIRST INCIDENCE	565	456	659	729 (T)

STATISTICAL TESTS

POLY 3	P=0.406N	P=0.122N	P=0.362N	P=0.233N
POLY 1.5	P=0.408N	P=0.125N	P=0.366N	P=0.238N
POLY 6	P=0.403N	P=0.118N	P=0.354N	P=0.226N
COCH-ARM / FISHERS	P=0.403N	P=0.134N	P=0.370N	P=0.243N
MAX-ISO-POLY-3	P=0.201N	P=0.065N	P=0.247N	P=0.142N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Infiltration Cellular

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Infiltration Cellular Lymphocyte

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	2/45.74	2/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	4.4%	4.5%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.220N	P=0.514	P=0.508	P=0.492N
POLY 1.5	P=0.224N	P=0.509	P=0.504	P=0.496N
POLY 6	P=0.213N	P=0.520	P=0.514	P=0.487N
COCH-ARM / FISHERS	P=0.227N	P=0.500	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.245N	P=0.296	P=0.289	P=0.158N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Infiltration Cellular Mixed Cell

LESION RATES

OVERALL (a)	2/50 (4%)	4/50 (8%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/44.38	4/46.12	2/44.97	0/45.74
POLY-3 PERCENT (g)	4.5%	8.7%	4.5%	0%
TERMINAL (d)	0/35 (0%)	3/40 (8%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	659	622	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.083N	P=0.355	P=0.689N	P=0.230N
POLY 1.5	P=0.086N	P=0.349	P=0.692N	P=0.234N
POLY 6	P=0.080N	P=0.362	P=0.686N	P=0.226N
COCH-ARM / FISHERS	P=0.088N	P=0.339	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.108N	P=0.219	P=0.494N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Mixed Cell Focus

LESION RATES

OVERALL (a)	2/50 (4%)	5/50 (10%)	7/50 (14%)	15/50 (30%)
POLY-3 RATE (b)	2/43.97	5/45.74	7/44.97	15/46.46
POLY-3 PERCENT (g)	4.6%	10.9%	15.6%	32.3%
TERMINAL (d)	1/35 (3%)	5/40 (13%)	7/40 (18%)	12/40 (30%)
FIRST INCIDENCE	727	729 (T)	729 (T)	577

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.232	P=0.084	P<0.001**
POLY 1.5	P<0.001**	P=0.227	P=0.081	P<0.001**
POLY 6	P<0.001**	P=0.240	P=0.087	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.218	P=0.080	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.135	P=0.043*	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Necrosis Focal

LESION RATES

OVERALL (a)	2/50 (4%)	5/50 (10%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	2/44.90	5/47.37	2/44.97	2/45.74
POLY-3 PERCENT (g)	4.5%	10.6%	4.5%	4.4%
TERMINAL (d)	0/35 (0%)	2/40 (5%)	2/40 (5%)	2/40 (5%)
FIRST INCIDENCE	443	446	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.371N	P=0.239	P=0.693N	P=0.687N
POLY 1.5	P=0.375N	P=0.231	P=0.693	P=0.691N
POLY 6	P=0.364N	P=0.249	P=0.691N	P=0.681N
COCH-ARM / FISHERS	P=0.377N	P=0.218	P=0.691N	P=0.691N
MAX-ISO-POLY-3	P=0.427N	P=0.141	P=0.499N	P=0.492N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Tension Lipidosis

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/44.33	0/45.74	1/45.27	2/45.91
POLY-3 PERCENT (g)	2.3%	0%	2.2%	4.4%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	625	---	646	684

STATISTICAL TESTS

POLY 3	P=0.247	P=0.494N	P=0.756N	P=0.512
POLY 1.5	P=0.244	P=0.496N	P=0.758N	P=0.506
POLY 6	P=0.252	P=0.491N	P=0.752N	P=0.521
COCH-ARM / FISHERS	P=0.243	P=0.500N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.252	P=0.158N	P=0.493N	P=0.294

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver: Centrilobular
 Necrosis

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/44.17	1/46.33	1/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	2.2%	2.2%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	672	540	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.336N	P=0.750N	P=0.757N	P=0.493N
POLY 1.5	P=0.339N	P=0.753N	P=0.759N	P=0.496N
POLY 6	P=0.333N	P=0.745N	P=0.754N	P=0.488N
COCH-ARM / FISHERS	P=0.339N	P=0.753N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.339N	P=0.486N	P=0.494N	P=0.158N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver: Hepatocyte
 Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	6/50 (12%)	3/50 (6%)	9/50 (18%)	22/50 (44%)
POLY-3 RATE (b)	6/44.73	3/46.51	9/44.97	22/46.19
POLY-3 PERCENT (g)	13.4%	6.5%	20%	47.6%
TERMINAL (d)	5/35 (14%)	2/40 (5%)	9/40 (23%)	20/40 (50%)
FIRST INCIDENCE	443	446	729 (T)	654

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.223N	P=0.290	P<0.001**
POLY 1.5	P<0.001**	P=0.230N	P=0.287	P<0.001**
POLY 6	P<0.001**	P=0.214N	P=0.298	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.243N	P=0.288	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.137N	P=0.203	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver: Kupffer Cell
 Pigmentation**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.22	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	659	---	---	---

STATISTICAL TESTS

POLY 3	P=0.353N	P=0.230N	P=0.233N	P=0.230N
POLY 1.5	P=0.352N	P=0.232N	P=0.235N	P=0.233N
POLY 6	P=0.355N	P=0.227N	P=0.231N	P=0.225N
COCH-ARM / FISHERS	P=0.350N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.036N*	P=0.076N	P=0.076N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung
 Hemorrhage**

LESION RATES

OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	7/50 (14%)
POLY-3 RATE (b)	2/44.38	3/45.74	3/44.97	7/47.05
POLY-3 PERCENT (g)	4.5%	6.6%	6.7%	14.9%
TERMINAL (d)	0/35 (0%)	3/40 (8%)	3/40 (8%)	5/40 (13%)
FIRST INCIDENCE	659	729 (T)	729 (T)	420

STATISTICAL TESTS

POLY 3	P=0.045*	P=0.514	P=0.506	P=0.094
POLY 1.5	P=0.042*	P=0.510	P=0.503	P=0.087
POLY 6	P=0.049*	P=0.518	P=0.510	P=0.101
COCH-ARM / FISHERS	P=0.038*	P=0.500	P=0.500	P=0.080
MAX-ISO-POLY-3	P=0.065	P=0.338	P=0.330	P=0.052

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung
 Infiltration Cellular Histiocyte**

LESION RATES

OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	2/43.96	1/45.89	1/44.97	4/46.53
POLY-3 PERCENT (g)	4.6%	2.2%	2.2%	8.6%
TERMINAL (d)	2/35 (6%)	0/40 (0%)	1/40 (3%)	2/40 (5%)
FIRST INCIDENCE	729 (T)	689	729 (T)	463

STATISTICAL TESTS

POLY 3	P=0.120	P=0.485N	P=0.492N	P=0.364
POLY 1.5	P=0.116	P=0.490N	P=0.496N	P=0.352
POLY 6	P=0.124	P=0.477N	P=0.486N	P=0.380
COCH-ARM / FISHERS	P=0.113	P=0.500N	P=0.500N	P=0.339
MAX-ISO-POLY-3	P=0.171	P=0.272N	P=0.276N	P=0.228

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung
 Thrombosis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.760N	(e)	P=0.505	(e)
POLY 1.5	P=0.762N	(e)	P=0.502	(e)
POLY 6	P=0.757N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.763N	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.402	(e)	P=0.164	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung: Alveolar Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/45.23	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	659	---

STATISTICAL TESTS

POLY 3	P=0.486N	P=0.492N	P=0.754N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.757N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.750N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.491N	P=0.158N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Lymph Node, Mandibular Atrophy

LESION RATES

OVERALL (a)	0/46 (0%)	0/49 (0%)	1/47 (2%)	0/49 (0%)
POLY-3 RATE (b)	0/40.22	0/45.51	1/42.96	0/44.74
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/32 (0%)	0/40 (0%)	0/37 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	152	---

STATISTICAL TESTS

POLY 3	P=0.754N	(e)	P=0.513	(e)
POLY 1.5	P=0.756N	(e)	P=0.510	(e)
POLY 6	P=0.752N	(e)	P=0.516	(e)
COCH-ARM / FISHERS	P=0.757N	(e)	P=0.505	(e)
MAX-ISO-POLY-3	P=0.413	(e)	P=0.173	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Lymph Node, Mandibular Hemorrhage

LESION RATES

OVERALL (a)	0/46 (0%)	0/49 (0%)	2/47 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/40.22	0/45.51	2/42.60	0/44.74
POLY-3 PERCENT (g)	0%	0%	4.7%	0%
TERMINAL (d)	0/32 (0%)	0/40 (0%)	1/37 (3%)	0/39 (0%)
FIRST INCIDENCE	---	---	520	---

STATISTICAL TESTS

POLY 3	P=0.611N	(e)	P=0.250	(e)
POLY 1.5	P=0.615N	(e)	P=0.246	(e)
POLY 6	P=0.606N	(e)	P=0.255	(e)
COCH-ARM / FISHERS	P=0.615N	(e)	P=0.253	(e)
MAX-ISO-POLY-3	P=0.282	(e)	P=0.087	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lymph Node, Mandibular
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	4/46 (9%)	3/49 (6%)	4/47 (9%)	2/49 (4%)
POLY-3 RATE (b)	4/40.58	3/45.67	4/42.23	2/44.74
POLY-3 PERCENT (g)	9.9%	6.6%	9.5%	4.5%
TERMINAL (d)	2/32 (6%)	2/40 (5%)	3/37 (8%)	2/39 (5%)
FIRST INCIDENCE	681	689	659	729 (T)

STATISTICAL TESTS

POLY 3	P=0.288N	P=0.436N	P=0.622N	P=0.293N
POLY 1.5	P=0.291N	P=0.445N	P=0.627N	P=0.300N
POLY 6	P=0.283N	P=0.426N	P=0.616N	P=0.284N
COCH-ARM / FISHERS	P=0.290N	P=0.464N	P=0.631N	P=0.309N
MAX-ISO-POLY-3	P=0.301N	P=0.298N	P=0.476N	P=0.175N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lymph Node, Mandibular
 Pigmentation**

LESION RATES

OVERALL (a)	4/46 (9%)	4/49 (8%)	4/47 (9%)	3/49 (6%)
POLY-3 RATE (b)	4/40.96	4/45.67	4/42.28	3/44.96
POLY-3 PERCENT (g)	9.8%	8.8%	9.5%	6.7%
TERMINAL (d)	2/32 (6%)	3/40 (8%)	3/37 (8%)	2/39 (5%)
FIRST INCIDENCE	547	689	643	670

STATISTICAL TESTS

POLY 3	P=0.396N	P=0.582N	P=0.626N	P=0.449N
POLY 1.5	P=0.401N	P=0.590N	P=0.629N	P=0.457N
POLY 6	P=0.387N	P=0.574N	P=0.621N	P=0.438N
COCH-ARM / FISHERS	P=0.401N	P=0.607N	P=0.631N	P=0.464N
MAX-ISO-POLY-3	P=0.500N	P=0.437N	P=0.480N	P=0.307N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Angiectasis**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/46 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/41.63	0/43.82
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/37 (0%)	0/39 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Atrophy**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/46 (4%)	0/48 (0%)
POLY-3 RATE (b)	1/44.12	1/45.74	2/42.62	0/43.82
POLY-3 PERCENT (g)	2.3%	2.2%	4.7%	0%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	1/37 (3%)	0/39 (0%)
FIRST INCIDENCE	687	729 (T)	152	---

STATISTICAL TESTS

POLY 3	P=0.313N	P=0.753N	P=0.488	P=0.501N
POLY 1.5	P=0.317N	P=0.755N	P=0.483	P=0.505N
POLY 6	P=0.308N	P=0.749N	P=0.494	P=0.496N
COCH-ARM / FISHERS	P=0.318N	P=0.753N	P=0.468	P=0.510N
MAX-ISO-POLY-3	P=0.288N	P=0.489N	P=0.271	P=0.161N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/46 (2%)	0/48 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	1/41.63	0/43.82
POLY-3 PERCENT (g)	0%	0%	2.4%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/37 (3%)	0/39 (0%)
FIRST INCIDENCE	---	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.764N	(e)	P=0.489	(e)
POLY 1.5	P=0.766N	(e)	P=0.486	(e)
POLY 6	P=0.761N	(e)	P=0.493	(e)
COCH-ARM / FISHERS	P=0.767N	(e)	P=0.479	(e)
MAX-ISO-POLY-3	P=0.387	(e)	P=0.153	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Lymph Node, Mesenteric Hemorrhage

LESION RATES

OVERALL (a)	1/50 (2%)	4/50 (8%)	2/46 (4%)	1/48 (2%)
POLY-3 RATE (b)	1/43.96	4/45.74	2/41.63	1/43.82
POLY-3 PERCENT (g)	2.3%	8.8%	4.8%	2.3%
TERMINAL (d)	1/35 (3%)	4/40 (10%)	2/37 (5%)	1/39 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.321N	P=0.191	P=0.481	P=0.760
POLY 1.5	P=0.328N	P=0.187	P=0.476	P=0.756
POLY 6	P=0.311N	P=0.196	P=0.488	P=0.755N
COCH-ARM / FISHERS	P=0.334N	P=0.181	P=0.468	P=0.742
MAX-ISO-POLY-3	P=0.382N	P=0.095	P=0.265	P=0.498

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lymph Node, Mesenteric
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/50 (0%)	3/50 (6%)	5/46 (11%)	1/48 (2%)
POLY-3 RATE (b)	0/43.96	3/45.74	5/42.27	1/44.10
POLY-3 PERCENT (g)	0%	6.6%	11.8%	2.3%
TERMINAL (d)	0/35 (0%)	3/40 (8%)	4/37 (11%)	0/39 (0%)
FIRST INCIDENCE	---	729 (T)	520	654

STATISTICAL TESTS

POLY 3	P=0.402N	P=0.126	P=0.027*	P=0.501
POLY 1.5	P=0.414N	P=0.124	P=0.026*	P=0.496
POLY 6	P=0.384N	P=0.129	P=0.029*	P=0.507
COCH-ARM / FISHERS	P=0.424N	P=0.121	P=0.022*	P=0.490
MAX-ISO-POLY-3	P=0.117	P=0.044*	P=0.008**	P=0.162

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Lymph Node: Iliac
 Hematopoietic Cell Proliferation

LESION RATES

OVERALL (a)	0/10 (0%)	2/5 (40%)	0/4 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/8.38	2/4.22	0/3.78	0/1.00
POLY-3 PERCENT (g)	0%	47.4%	0%	0%
TERMINAL (d)	0/4 (0%)	1/2 (50%)	0/3 (0%)	0/1 (0%)
FIRST INCIDENCE	---	456	---	---

STATISTICAL TESTS

POLY 3	P=0.848N	P=0.061	(e)	(e)
POLY 1.5	P=0.849N	P=0.063	(e)	(e)
POLY 6	P=0.844N	P=0.060	(e)	(e)
COCH-ARM / FISHERS	P=0.829N	P=0.095	(e)	(e)
MAX-ISO-POLY-3	P=0.449	P=0.015*	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Mammary Gland
 Hyperplasia**

LESION RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	5/50 (10%)	2/50 (4%)
POLY-3 RATE (b)	4/45.03	3/46.49	5/44.97	2/45.74
POLY-3 PERCENT (g)	8.9%	6.5%	11.1%	4.4%
TERMINAL (d)	0/35 (0%)	2/40 (5%)	5/40 (13%)	2/40 (5%)
FIRST INCIDENCE	589	456	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.287N	P=0.483N	P=0.499	P=0.330N
POLY 1.5	P=0.290N	P=0.487N	P=0.499	P=0.334N
POLY 6	P=0.283N	P=0.480N	P=0.498	P=0.326N
COCH-ARM / FISHERS	P=0.288N	P=0.500N	P=0.500	P=0.339N
MAX-ISO-POLY-3	P=0.350N	P=0.334N	P=0.362	P=0.197N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Mesentery
 Hemorrhage**

LESION RATES

OVERALL (a)	0/7 (0%)	0/9 (0%)	0/14 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/6.36	0/7.66	0/13.74	0/7.45
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/5 (0%)	0/6 (0%)	0/13 (0%)	0/6 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Mesentery: Fat
 Necrosis**

LESION RATES

OVERALL (a)	7/7 (100%)	6/9 (67%)	13/14 (93%)	8/8 (100%)
POLY-3 RATE (b)	7/7.00	6/8.62	13/14.00	8/8.00
POLY-3 PERCENT (g)	100%	69.6%	92.9%	100%
TERMINAL (d)	5/5 (100%)	4/6 (67%)	12/13 (92%)	6/6 (100%)
FIRST INCIDENCE	622	446	659	577

STATISTICAL TESTS

POLY 3	P=0.290	P=0.162N	P=0.636N	(e)
POLY 1.5	P=0.271	P=0.150N	P=0.636N	(e)
POLY 6	P=0.322	P=0.188N	P=0.636N	(e)
COCH-ARM / FISHERS	P=0.260	P=0.150N	P=0.667N	(e)
MAX-ISO-POLY-3	P=0.210	P=0.049N*	P=0.273N	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Nose
 Foreign Body

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.12	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Nose
 Inflammation Chronic**

LESION RATES

OVERALL (a)	1/50 (2%)	3/49 (6%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	1/43.96	3/45.12	0/44.97	4/46.48
POLY-3 PERCENT (g)	2.3%	6.7%	0%	8.6%
TERMINAL (d)	1/35 (3%)	3/40 (8%)	0/40 (0%)	3/40 (8%)
FIRST INCIDENCE	729 (T)	729 (T)	---	463

STATISTICAL TESTS

POLY 3	P=0.147	P=0.315	P=0.495N	P=0.196
POLY 1.5	P=0.142	P=0.309	P=0.498N	P=0.188
POLY 6	P=0.153	P=0.323	P=0.492N	P=0.206
COCH-ARM / FISHERS	P=0.137	P=0.301	P=0.500N	P=0.181
MAX-ISO-POLY-3	P=0.127	P=0.165	P=0.158N	P=0.100

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Ovary
 Angiectasis**

LESION RATES

OVERALL (a)	0/49 (0%)	4/50 (8%)	2/49 (4%)	1/48 (2%)
POLY-3 RATE (b)	0/42.96	4/45.74	2/43.97	1/44.48
POLY-3 PERCENT (g)	0%	8.8%	4.6%	2.3%
TERMINAL (d)	0/34 (0%)	4/40 (10%)	2/39 (5%)	1/39 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.408N	P=0.068	P=0.242	P=0.507
POLY 1.5	P=0.419N	P=0.067	P=0.240	P=0.502
POLY 6	P=0.394N	P=0.071	P=0.246	P=0.513
COCH-ARM / FISHERS	P=0.433N	P=0.061	P=0.247	P=0.495
MAX-ISO-POLY-3	P=0.182	P=0.025*	P=0.081	P=0.168

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Ovary
Cyst

LESION RATES

OVERALL (a)	11/49 (22%)	14/50 (28%)	10/49 (20%)	15/48 (31%)
POLY-3 RATE (b)	11/44.08	14/47.29	10/44.36	15/44.71
POLY-3 PERCENT (g)	25%	29.6%	22.5%	33.6%
TERMINAL (d)	7/34 (21%)	10/40 (25%)	9/39 (23%)	14/39 (36%)
FIRST INCIDENCE	589	540	618	670

STATISTICAL TESTS

POLY 3	P=0.232	P=0.397	P=0.493N	P=0.256
POLY 1.5	P=0.224	P=0.378	P=0.497N	P=0.242
POLY 6	P=0.240	P=0.420	P=0.489N	P=0.271
COCH-ARM / FISHERS	P=0.219	P=0.343	P=0.500N	P=0.227
MAX-ISO-POLY-3	P=0.306	P=0.315	P=0.393N	P=0.189

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Ovary
 Hemorrhage**

LESION RATES

OVERALL (a)	4/49 (8%)	0/50 (0%)	1/49 (2%)	6/48 (13%)
POLY-3 RATE (b)	4/43.17	0/45.74	1/43.97	6/44.76
POLY-3 PERCENT (g)	9.3%	0%	2.3%	13.4%
TERMINAL (d)	3/34 (9%)	0/40 (0%)	1/39 (3%)	5/39 (13%)
FIRST INCIDENCE	672	---	729 (T)	654

STATISTICAL TESTS

POLY 3	P=0.030*	P=0.053N	P=0.173N	P=0.392
POLY 1.5	P=0.029*	P=0.055N	P=0.176N	P=0.376
POLY 6	P=0.032*	P=0.051N	P=0.168N	P=0.413
COCH-ARM / FISHERS	P=0.030*	P=0.056N	P=0.181N	P=0.357
MAX-ISO-POLY-3	P=0.050*	P=0.019N*	P=0.082N	P=0.277

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Ovary: Interstitial Cell
Hyperplasia

LESION RATES

OVERALL (a)	1/49 (2%)	0/50 (0%)	2/49 (4%)	0/48 (0%)
POLY-3 RATE (b)	1/43.13	0/45.74	2/43.97	0/44.48
POLY-3 PERCENT (g)	2.3%	0%	4.6%	0%
TERMINAL (d)	0/34 (0%)	0/40 (0%)	2/39 (5%)	0/39 (0%)
FIRST INCIDENCE	684	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.426N	P=0.488N	P=0.507	P=0.494N
POLY 1.5	P=0.431N	P=0.491N	P=0.503	P=0.498N
POLY 6	P=0.420N	P=0.485N	P=0.511	P=0.488N
COCH-ARM / FISHERS	P=0.434N	P=0.495N	P=0.500	P=0.505N
MAX-ISO-POLY-3	P=0.337N	P=0.157N	P=0.288	P=0.160N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pancreas
 Atrophy**

LESION RATES

OVERALL (a)	1/49 (2%)	0/50 (0%)	2/50 (4%)	4/49 (8%)
POLY-3 RATE (b)	1/43.53	0/45.74	2/45.63	4/44.82
POLY-3 PERCENT (g)	2.3%	0%	4.4%	8.9%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	1/40 (3%)	4/40 (10%)
FIRST INCIDENCE	729 (T)	---	508	729 (T)

STATISTICAL TESTS

POLY 3	P=0.040*	P=0.490N	P=0.516	P=0.187
POLY 1.5	P=0.039*	P=0.492N	P=0.512	P=0.183
POLY 6	P=0.041*	P=0.487N	P=0.522	P=0.195
COCH-ARM / FISHERS	P=0.039*	P=0.495N	P=0.508	P=0.181
MAX-ISO-POLY-3	P=0.051	P=0.157N	P=0.297	P=0.092

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pancreas
 Cyst**

LESION RATES

OVERALL (a)	0/49 (0%)	1/50 (2%)	3/50 (6%)	1/49 (2%)
POLY-3 RATE (b)	0/43.53	1/45.74	3/45.63	1/44.82
POLY-3 PERCENT (g)	0%	2.2%	6.6%	2.2%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	2/40 (5%)	1/40 (3%)
FIRST INCIDENCE	---	729 (T)	508	729 (T)

STATISTICAL TESTS

POLY 3	P=0.642	P=0.510	P=0.127	P=0.506
POLY 1.5	P=0.635	P=0.508	P=0.125	P=0.503
POLY 6	P=0.651	P=0.513	P=0.130	P=0.510
COCH-ARM / FISHERS	P=0.632	P=0.505	P=0.125	P=0.500
MAX-ISO-POLY-3	P=0.177	P=0.170	P=0.044*	P=0.166

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pancreas: Acinus
 Cytoplasmic Alteration**

LESION RATES

OVERALL (a)	1/49 (2%)	1/50 (2%)	3/50 (6%)	1/49 (2%)
POLY-3 RATE (b)	1/43.90	1/45.74	3/45.27	1/45.33
POLY-3 PERCENT (g)	2.3%	2.2%	6.6%	2.2%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	625	729 (T)	646	577

STATISTICAL TESTS

POLY 3	P=0.568N	P=0.752N	P=0.316	P=0.753N
POLY 1.5	P=0.574N	P=0.752N	P=0.314	P=0.757N
POLY 6	P=0.558N	P=0.750N	P=0.320	P=0.748N
COCH-ARM / FISHERS	P=0.578N	P=0.747N	P=0.316	P=0.753N
MAX-ISO-POLY-3	P=0.462	P=0.488N	P=0.164	P=0.490N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Parathyroid Gland
 Cyst**

LESION RATES

OVERALL (a)	0/48 (0%)	1/49 (2%)	1/45 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/42.53	1/44.74	1/41.25	2/45.74
POLY-3 PERCENT (g)	0%	2.2%	2.4%	4.4%
TERMINAL (d)	0/34 (0%)	1/39 (3%)	1/38 (3%)	2/40 (5%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.250	P=0.510	P=0.494	P=0.254
POLY 1.5	P=0.246	P=0.508	P=0.490	P=0.250
POLY 6	P=0.255	P=0.513	P=0.499	P=0.259
COCH-ARM / FISHERS	P=0.242	P=0.505	P=0.484	P=0.258
MAX-ISO-POLY-3	P=0.154	P=0.170	P=0.155	P=0.090

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Peripheral Nerve
 Atrophy**

LESION RATES

OVERALL (a)	2/2 (100%)	0/1 (0%)	2/3 (67%)	1/1 (100%)
POLY-3 RATE (b)	2/2.00	0/0.61	2/2.70	1/1.00
POLY-3 PERCENT (g)	100%	0%	74.2%	100%
TERMINAL (d)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/0 (0%)
FIRST INCIDENCE	589	---	618	670

STATISTICAL TESTS

POLY 3	P=0.823	P=0.333N	P=0.702N	(e)
POLY 1.5	P=0.748	P=0.333N	P=0.636N	(e)
POLY 6	P=0.935	P=0.333N	P=0.845N	(e)
COCH-ARM / FISHERS	P=0.671	P=0.333N	P=0.600N	(e)
MAX-ISO-POLY-3	P=0.444N	P<0.001N**	P=0.230N	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Angiectasis**

LESION RATES

OVERALL (a)	1/49 (2%)	1/47 (2%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	1/43.12	1/43.71	2/44.97	2/45.74
POLY-3 PERCENT (g)	2.3%	2.3%	4.5%	4.4%
TERMINAL (d)	1/35 (3%)	1/39 (3%)	2/40 (5%)	2/40 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.448	P=0.758N	P=0.515	P=0.521
POLY 1.5	P=0.443	P=0.759	P=0.511	P=0.514
POLY 6	P=0.453	P=0.752N	P=0.520	P=0.529
COCH-ARM / FISHERS	P=0.441	P=0.742	P=0.508	P=0.508
MAX-ISO-POLY-3	P=0.479	P=0.495N	P=0.296	P=0.302

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Cyst**

LESION RATES

OVERALL (a)	1/49 (2%)	1/47 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.12	1/43.71	0/44.97	1/45.74
POLY-3 PERCENT (g)	2.3%	2.3%	0%	2.2%
TERMINAL (d)	1/35 (3%)	1/39 (3%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.672	P=0.758N	P=0.492N	P=0.747N
POLY 1.5	P=0.670	P=0.759	P=0.494N	P=0.752N
POLY 6	P=0.675	P=0.752N	P=0.489N	P=0.742N
COCH-ARM / FISHERS	P=0.670	P=0.742	P=0.495N	P=0.747N
MAX-ISO-POLY-3	P=0.531N	P=0.495N	P=0.157N	P=0.483N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis
 Hyperplasia Focal**

LESION RATES

OVERALL (a)	5/49 (10%)	8/47 (17%)	7/50 (14%)	7/50 (14%)
POLY-3 RATE (b)	5/43.12	8/43.71	7/44.97	7/45.96
POLY-3 PERCENT (g)	11.6%	18.3%	15.6%	15.2%
TERMINAL (d)	5/35 (14%)	8/39 (21%)	7/40 (18%)	6/40 (15%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	670

STATISTICAL TESTS

POLY 3	P=0.565	P=0.283	P=0.409	P=0.424
POLY 1.5	P=0.551	P=0.271	P=0.401	P=0.410
POLY 6	P=0.580N	P=0.300	P=0.419	P=0.446
COCH-ARM / FISHERS	P=0.541	P=0.249	P=0.394	P=0.394
MAX-ISO-POLY-3	P=0.443	P=0.196	P=0.297	P=0.313

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Salivary Glands
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	10/49 (20%)	12/49 (24%)	2/49 (4%)	7/50 (14%)
POLY-3 RATE (b)	10/43.80	12/46.06	2/43.97	7/45.74
POLY-3 PERCENT (g)	22.8%	26.1%	4.6%	15.3%
TERMINAL (d)	8/35 (23%)	10/40 (25%)	2/39 (5%)	7/40 (18%)
FIRST INCIDENCE	625	622	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.233N	P=0.456	P=0.013N*	P=0.262N
POLY 1.5	P=0.238N	P=0.440	P=0.013N*	P=0.272N
POLY 6	P=0.227N	P=0.475	P=0.012N*	P=0.251N
COCH-ARM / FISHERS	P=0.245N	P=0.405	P=0.014N*	P=0.282N
MAX-ISO-POLY-3	P=0.060N	P=0.364	P=0.005N**	P=0.186N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Salivary Glands: Submandibular Gland
 Cytoplasmic Alteration**

LESION RATES

OVERALL (a)	0/49 (0%)	17/49 (35%)	40/49 (82%)	45/50 (90%)
POLY-3 RATE (b)	0/43.22	17/45.89	40/44.92	45/48.48
POLY-3 PERCENT (g)	0%	37.1%	89%	92.8%
TERMINAL (d)	0/35 (0%)	16/40 (40%)	37/39 (95%)	39/40 (98%)
FIRST INCIDENCE	---	622	618	158

STATISTICAL TESTS

POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Skin
 Ulcer

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/44.32	0/45.74	2/44.97	0/45.74
POLY-3 PERCENT (g)	4.5%	0%	4.5%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	681	---	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.290N	P=0.230N	P=0.689N	P=0.230N
POLY 1.5	P=0.292N	P=0.232N	P=0.691N	P=0.234N
POLY 6	P=0.287N	P=0.228N	P=0.685N	P=0.226N
COCH-ARM / FISHERS	P=0.292N	P=0.247N	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.126N	P=0.076N	P=0.493N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Spleen
 Hematopoietic Cell Proliferation**

LESION RATES

OVERALL (a)	28/50 (56%)	29/50 (58%)	32/50 (64%)	22/50 (44%)
POLY-3 RATE (b)	28/45.72	29/49.24	32/47.50	22/47.92
POLY-3 PERCENT (g)	61.2%	58.9%	67.4%	45.9%
TERMINAL (d)	20/35 (57%)	22/40 (55%)	26/40 (65%)	17/40 (43%)
FIRST INCIDENCE	565	446	442	420

STATISTICAL TESTS

POLY 3	P=0.043N*	P=0.491N	P=0.342	P=0.097N
POLY 1.5	P=0.049N*	P=0.545N	P=0.309	P=0.118N
POLY 6	P=0.039N*	P=0.445N	P=0.377	P=0.082N
COCH-ARM / FISHERS	P=0.059N	P=0.500	P=0.270	P=0.159N
MAX-ISO-POLY-3	P=0.071N	P=0.409N	P=0.270	P=0.070N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Spleen: Lymphoid Follicle
 Atrophy**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/43.96	0/45.74	1/45.45	2/46.42
POLY-3 PERCENT (g)	0%	0%	2.2%	4.3%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	586	577

STATISTICAL TESTS

POLY 3	P=0.112	(e)	P=0.507	P=0.250
POLY 1.5	P=0.109	(e)	P=0.503	P=0.244
POLY 6	P=0.117	(e)	P=0.511	P=0.258
COCH-ARM / FISHERS	P=0.106	(e)	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.098	(e)	P=0.167	P=0.088

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Spleen: Lymphoid Follicle
 Hyperplasia**

LESION RATES

OVERALL (a)	7/50 (14%)	6/50 (12%)	15/50 (30%)	8/50 (16%)
POLY-3 RATE (b)	7/44.13	6/45.74	15/45.36	8/45.74
POLY-3 PERCENT (g)	15.9%	13.1%	33.1%	17.5%
TERMINAL (d)	6/35 (17%)	6/40 (15%)	14/40 (35%)	8/40 (20%)
FIRST INCIDENCE	684	729 (T)	618	729 (T)

STATISTICAL TESTS

POLY 3	P=0.567N	P=0.472N	P=0.047*	P=0.530
POLY 1.5	P=0.567	P=0.481N	P=0.045*	P=0.515
POLY 6	P=0.547N	P=0.461N	P=0.052	P=0.550
COCH-ARM / FISHERS	P=0.558	P=0.500N	P=0.045*	P=0.500
MAX-ISO-POLY-3	P=0.169	P=0.358N	P=0.029*	P=0.418

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Forestomach: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	0/43.96	1/45.74	1/44.97	3/46.01
POLY-3 PERCENT (g)	0%	2.2%	2.2%	6.5%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	670

STATISTICAL TESTS

POLY 3	P=0.079	P=0.508	P=0.505	P=0.127
POLY 1.5	P=0.077	P=0.505	P=0.502	P=0.123
POLY 6	P=0.083	P=0.512	P=0.508	P=0.133
COCH-ARM / FISHERS	P=0.075	P=0.500	P=0.500	P=0.121
MAX-ISO-POLY-3	P=0.054	P=0.168	P=0.164	P=0.045*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Glandular
 Cyst**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/35 (6%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	---	---

STATISTICAL TESTS

POLY 3	P=0.354N	P=0.228N	P=0.232N	P=0.228N
POLY 1.5	P=0.353N	P=0.231N	P=0.235N	P=0.233N
POLY 6	P=0.357N	P=0.224N	P=0.228N	P=0.222N
COCH-ARM / FISHERS	P=0.350N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.036N*	P=0.076N	P=0.076N	P=0.076N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Glandular
 Erosion**

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/44.17	1/46.33	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	2.2%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	672	540	---	---

STATISTICAL TESTS

POLY 3	P=0.374N	P=0.750N	P=0.496N	P=0.493N
POLY 1.5	P=0.376N	P=0.753N	P=0.498N	P=0.496N
POLY 6	P=0.373N	P=0.745N	P=0.494N	P=0.488N
COCH-ARM / FISHERS	P=0.376N	P=0.753N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.486N	P=0.158N	P=0.158N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Glandular: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.96	0/45.74	0/44.97	1/45.74
POLY-3 PERCENT (g)	2.3%	0%	0%	2.2%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	0/40 (0%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	---	---	729 (T)

STATISTICAL TESTS

POLY 3	P=0.515	P=0.492N	P=0.495N	P=0.752N
POLY 1.5	P=0.513	P=0.495N	P=0.498N	P=0.756N
POLY 6	P=0.516	P=0.488N	P=0.492N	P=0.746N
COCH-ARM / FISHERS	P=0.514	P=0.500N	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.405N	P=0.158N	P=0.158N	P=0.488N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thymus
 Atrophy**

LESION RATES

OVERALL (a)	2/47 (4%)	3/46 (7%)	4/46 (9%)	3/46 (7%)
POLY-3 RATE (b)	2/41.60	3/43.34	4/43.45	3/43.84
POLY-3 PERCENT (g)	4.8%	6.9%	9.2%	6.8%
TERMINAL (d)	0/33 (0%)	1/37 (3%)	1/38 (3%)	0/37 (0%)
FIRST INCIDENCE	672	456	152	420

STATISTICAL TESTS

POLY 3	P=0.582	P=0.519	P=0.357	P=0.524
POLY 1.5	P=0.569	P=0.510	P=0.347	P=0.510
POLY 6	P=0.596	P=0.528	P=0.370	P=0.538
COCH-ARM / FISHERS	P=0.553	P=0.490	P=0.328	P=0.490
MAX-ISO-POLY-3	P=0.466	P=0.344	P=0.222	P=0.349

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thymus
 Cyst**

LESION RATES

OVERALL (a)	1/47 (2%)	0/46 (0%)	0/46 (0%)	0/46 (0%)
POLY-3 RATE (b)	1/41.44	0/42.41	0/41.84	0/42.24
POLY-3 PERCENT (g)	2.4%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/37 (0%)	0/38 (0%)	0/37 (0%)
FIRST INCIDENCE	672	---	---	---

STATISTICAL TESTS

POLY 3	P=0.596N	P=0.495N	P=0.498N	P=0.496N
POLY 1.5	P=0.594N	P=0.498N	P=0.501N	P=0.500N
POLY 6	P=0.598N	P=0.492N	P=0.494N	P=0.491N
COCH-ARM / FISHERS	P=0.590N	P=0.505N	P=0.505N	P=0.505N
MAX-ISO-POLY-3	P=0.133N	P=0.160N	P=0.160N	P=0.160N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thymus
 Hyperplasia Lymphoid**

LESION RATES

OVERALL (a)	0/47 (0%)	2/46 (4%)	0/46 (0%)	0/46 (0%)
POLY-3 RATE (b)	0/41.22	2/42.41	0/41.84	0/42.24
POLY-3 PERCENT (g)	0%	4.7%	0%	0%
TERMINAL (d)	0/33 (0%)	2/37 (5%)	0/38 (0%)	0/37 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.392N	P=0.243	(e)	(e)
POLY 1.5	P=0.397N	P=0.240	(e)	(e)
POLY 6	P=0.387N	P=0.248	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.242	(e)	(e)
MAX-ISO-POLY-3	P=0.266N	P=0.083	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thyroid Gland: Follicle
 Degeneration Focal**

LESION RATES

OVERALL (a)	26/50 (52%)	18/50 (36%)	20/48 (42%)	19/50 (38%)
POLY-3 RATE (b)	26/46.73	18/47.62	20/43.53	19/47.90
POLY-3 PERCENT (g)	55.6%	37.8%	45.9%	39.7%
TERMINAL (d)	18/35 (51%)	13/40 (33%)	19/39 (49%)	13/40 (33%)
FIRST INCIDENCE	471	456	659	420

STATISTICAL TESTS

POLY 3	P=0.233N	P=0.060N	P=0.237N	P=0.086N
POLY 1.5	P=0.253N	P=0.064N	P=0.225N	P=0.097N
POLY 6	P=0.210N	P=0.057N	P=0.253N	P=0.075N
COCH-ARM / FISHERS	P=0.274N	P=0.079N	P=0.206N	P=0.114N
MAX-ISO-POLY-3	P=0.097N	P=0.040N*	P=0.183N	P=0.060N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell
 Hyperplasia**

LESION RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	2/48 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/45.74	2/43.27	1/45.74
POLY-3 PERCENT (g)	0%	2.2%	4.6%	2.2%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	2/39 (5%)	1/40 (3%)
FIRST INCIDENCE	---	729 (T)	729 (T)	729 (T)

STATISTICAL TESTS

POLY 3	P=0.612	P=0.508	P=0.233	P=0.508
POLY 1.5	P=0.605	P=0.505	P=0.231	P=0.504
POLY 6	P=0.621	P=0.512	P=0.238	P=0.513
COCH-ARM / FISHERS	P=0.600	P=0.500	P=0.237	P=0.500
MAX-ISO-POLY-3	P=0.242	P=0.168	P=0.075	P=0.168

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Urinary Bladder
 Infiltration Cellular Lymphocyte**

LESION RATES

OVERALL (a)	1/50 (2%)	4/50 (8%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	4/46.13	2/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	8.7%	4.5%	0%
TERMINAL (d)	1/35 (3%)	3/40 (8%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	618	729 (T)	---

STATISTICAL TESTS

POLY 3	P=0.116N	P=0.194	P=0.508	P=0.492N
POLY 1.5	P=0.120N	P=0.188	P=0.504	P=0.496N
POLY 6	P=0.111N	P=0.201	P=0.514	P=0.487N
COCH-ARM / FISHERS	P=0.125N	P=0.181	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.150N	P=0.098	P=0.289	P=0.158N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Urinary Bladder: Transitional Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/44.43	0/45.74	2/45.74	1/45.74
POLY-3 PERCENT (g)	2.3%	0%	4.4%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	589	---	442	729 (T)

STATISTICAL TESTS

POLY 3	P=0.622	P=0.494N	P=0.510	P=0.754N
POLY 1.5	P=0.618	P=0.496N	P=0.506	P=0.757N
POLY 6	P=0.627	P=0.492N	P=0.515	P=0.750N
COCH-ARM / FISHERS	P=0.618	P=0.500N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.401	P=0.158N	P=0.292	P=0.491N

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Uterus
 Angiectasis**

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	1/44.13	0/45.74	2/45.27	4/45.96
POLY-3 PERCENT (g)	2.3%	0%	4.4%	8.7%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	3/40 (8%)
FIRST INCIDENCE	684	---	646	670

STATISTICAL TESTS

POLY 3	P=0.042*	P=0.493N	P=0.509	P=0.191
POLY 1.5	P=0.041*	P=0.495N	P=0.504	P=0.185
POLY 6	P=0.044*	P=0.490N	P=0.515	P=0.200
COCH-ARM / FISHERS	P=0.041*	P=0.500N	P=0.500	P=0.181
MAX-ISO-POLY-3	P=0.055	P=0.158N	P=0.291	P=0.095

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/14/2008
 Time Report Requested: 08:06:09
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Uterus
 Hyperplasia Cystic**

LESION RATES

OVERALL (a)	44/50 (88%)	42/50 (84%)	42/50 (84%)	36/50 (72%)
POLY-3 RATE (b)	44/48.23	42/47.76	42/47.28	36/46.60
POLY-3 PERCENT (g)	91.2%	88%	88.8%	77.3%
TERMINAL (d)	33/35 (94%)	37/40 (93%)	36/40 (90%)	33/40 (83%)
FIRST INCIDENCE	443	502	508	611

STATISTICAL TESTS

POLY 3	P=0.024N*	P=0.419N	P=0.479N	P=0.047N*
POLY 1.5	P=0.024N*	P=0.383N	P=0.449N	P=0.042N*
POLY 6	P=0.024N*	P=0.471N	P=0.504N	P=0.054N
COCH-ARM / FISHERS	P=0.024N*	P=0.387N	P=0.387N	P=0.039N*
MAX-ISO-POLY-3	P=0.034N*	P=0.290N	P=0.341N	P=0.026N*

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/14/2008
Time Report Requested: 08:06:09
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***